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ABSTRACT 
 
The long-term impact of high sugar diets, a factor in the development of obesity and type-2 
diabetes, on the intestinal electrogenic sodium dependent glucose transport, the first portal of 
entry for glucose, is unknown. Here female C57bl/6 mice fed a normal standard chow diet, and 
20% sucrose in the drinking water for 8 months, or 35% sucrose inclusion in the diet for 12 
months were assessed. The drinking water sucrose treated mice developed obesity, whereas the 
solid dietary sucrose treated mice did not. Jejunal, ileal and colonic segment differences for 
electrogenic sodium dependent glucose transport kinetics, mRNA expression of sodium 
dependent glucose transporters, inflammatory mediators, and insulin signaling genes were 
assessed in all groups, as novel differences between segments were found in normal mice. Ex 
vivo intestinal Ussing chamber studies in normal mice characterizing the electrogenic sodium 
dependent glucose transport followed Hill Equation sigmoidal kinetics demonstrating low 
affinity, high capacity transport (Vmax of 100.8 ± 24.2 uA/cm2, K0.5 17.6 ± 0.9 mM) in the 
jejunum, high affinity, high capacity transport in the ileum (Vmax of 111.4 ± 17.5 uA /cm2, K0.5 
7.4 ± 1.0 mM) and the absence of transport in the colon. The preferential fit of the kinetics to the 
Hill Equation sigmoidal kinetics in each of the tissues, suggest mouse SGLT are working 
allosterically, or that there are multiple transporters working together to create the currents 
observed, more than in other mammals previously reported. Although segmental differences in 
inhibition by dapagliflozin, an SGLT2 inhibitor or phloridzin dihydrate, an SGLT1 inhibitor 
were evident, gene expression analysis of the SGLT 1- 6 could not fully explain these regional 
differences in kinetics. Non-the-less, the kinetics were highly modified by sucrose treatments, 
with a significant shift in the segmental transport, with a decrease in transport in the proximal 
segments of the intestine and increase distally in both groups. Most notable was, a significant 
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increase in the Vmax and K0.5 in the ileum of drinking water sucrose treated mice and the 
appearance of colonic glucose induced Hill equation kinetic transport in the solid dietary sucrose 
treated mice. Interestingly, the novel currents induced in mice treated with both drinking water 
sucrose and solid dietary sucrose diet were insensitive to inhibition by dapagliflozin or 
phloridzin dihydrate. This indicates that neither SGLT1 or SGLT2 were responsible for the 
changes in transport induced by the treatments. Paradoxically, the mRNA expression of SGLT1 
was significantly increased in the jejunum, ileum and colon of the drinking water sucrose treated 
mice and, SGLT2 was significantly increased in the jejunum and colon of the solid dietary 
sucrose treated mice. Additionally, none of the other SGLT family members known for glucose 
transport assessed by qRT-PCR could account for the observed kinetic changes. This is 
suggestive of an orphan sodium dependent glucose transporter or posttranslational modification 
of the identified transporters. Finally, these kinetic changes do not seem to be caused by 
inflammation or dysfunctions in the insulin signaling pathway, as the genes for both 
inflammatory mediators and insulin signaling were generally unchanged from control mice in 
both groups. The exceptions, not consistent in all segments, was a significant increase in TGF-b1 
in the drinking water sucrose treated mouse jejunum and ileum, and IRS-2 in the drinking water 
sucrose treated mouse jejunum. Identifying these novel segmental kinetic differences in 
electrogenic glucose absorption in the mouse intestine and the changes induced by chronical 
sucrose provided in the drinking water, including the appearance of a putative orphan 
transporter, not only adds to the understanding of the pathophysiology of the obesity, type-2 
diabetes but could direct future therapy.  
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1.0  INTRODUCTION  
 
During the last three decades, the occurrence of type 2 diabetes has doubled throughout 
America (Chen, Magliano, & Zimmet, 2012). This is in large part driven by the obesity epidemic 
resulting from the Standard American Diet (SAD) of high carbohydrate (often in the form of 
sucrose) and high fat (Grotto & Zied., 2010 ). Impaired glucose transport and insulin signaling in 
peripheral tissues has been well documented because of chronic consumption of SAD nutrient 
components and the onset of obesity and subsequently, type 2 diabetes. (La Fleur, Luijendijk, 
Van Rozen, Kalsbeek, & Adan, 2011; Maioli et al., 2016; Scheepers, Joost, & Schurmann, 2004; 
Withers et al., 1998). In addition, high fat diets and increased levels of glucose in the body are 
related to inflammation of tissues (Dhar, Dhar, Wu, & Desai, 2013; Maioli et al., 2016) 
However, the impact of high sucrose and the resulting obesity on intestinal glucose absorption is 
not known. In particular, the effect on electrogenic glucose absorption, the first port of energy for 
glucose across the intestine into the body, mediated by the sodium dependent glucose SGLT 
(SLC5A) gene family is unknown.  
This sodium dependent glucose absorption transports glucose along with sodium across 
the apical membrane of the enterocyte, and exits the basolateral membrane via a sodium 
independent transporter, and this process is known as active transport (Wright, 2013; Zhao & 
Keating, 2007). This active transport of sodium generates a current, which was used to indirectly 
characterize the movement of glucose and the transporters involved, in a Ussing Chamber. Hill 
Equation kinetics were then used to determine the affinity of the transporter, or the K0.5 and the 
capacity of the transporter, or the Vmax. The kinetics were used to attempt to define the 
complement or type of SGLT transporter in the intestinal tissue.  
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Thus far it has been reported in the literature that diets and beverages high in refined 
sugars, like sucrose result in high blood glucose levels in many species. These high blood 
glucose levels not only lead to obesity, insulin resistance and type 2 diabetes ((La Fleur et al., 
2011; Malik et al., 2010; Ritze et al., 2014; Tomás et al., 2002), but also contribute to increased 
methylglyoxal production, blood pressure, adipose tissue, inflammation, renal failure, 
neuropathy and peripheral vascular and cardiac disease (Dhar et al., 2013; Pawar et al., 2015; 
Scheepers et al., 2004) The impact of differences in route of administration (drinking water 
versus solid pellet dietary inclusion) on effects from chronic oral consumption of sucrose were 
investigated as this is not well known in the literature. High dietary sucrose, ingested in either 
form, mimics aspects of the diets of Western societies where large amounts of soft drinks and 
high sugar foods are chronically consumed (Maioli et al., 2016; Ritze et al., 2014). Specifically, 
normal or control mice were given standard chow and water. Whereas, mice treated with sucrose 
in the drinking water, a well characterized obesity model, were only given water treated with 
20% sucrose for 8 months, plus a standard chow diet. The third group of animals were fed a solid 
diet of 35% sucrose, but calorically similar to the standard chow and regular water for 1 year.  
After treatment, the intestines of each of the mouse groups were subject to electrogenic 
Ussing chamber glucose transport studies, including pharmacological inhibition. RT-qPCR gene 
expression analysis for sodium dependent glucose transporters, inflammatory mediators and 
insulin signaling genes was also performed on each segment to begin to elucidate the mechanism 
behind any changes in transport kinetics.  
Overall this work provides a better understanding of glucose absorption in a frequently 
used mammalian model, and the effect of chronic high sucrose consumption on it. Such high 
sucrose consumption, both in the diet and in beverages, contributes to obesity and the 
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development of type 2 diabetes, which affects a large portion of the population. Thus, this 
characterization provides insight for pharmacological treatment options of these diseases, such as 
inhibitors to the electrogenic glucose transporters in the intestine characterized in these models. 
The inhibitors could prevent the entry of glucose into the body, and the over secretion of insulin 
that drives the obesity and type 2 diabetes, and could possibly alter the course of the disease. 
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2.0 LITERATURE REVIEW 
2.1 Carbohydrate Digestion and Absorption  
 2.1.1 Gastrointestinal Tract Function and Anatomy and Carbohydrate Digestion. 
The gastrointestinal tract (GIT) is where digestion, transport and absorption of food, such as 
carbohydrates takes place. This review focuses on carbohydrates (glucose) and lipid (fat) 
metabolism and the interplay between the two. This knowledge is meant to give background to 
the following work that specifically focus on gastrointestinal glucose absorption.     
 To begin, understanding the anatomy and function of the GIT is important for the 
characterization of glucose absorption in the small intestine and preventing over or under 
consumption of nutrients and the diseases under study. The morphology of the gastrointestinal 
tract is dependent on the rate of food consumption, the kind of food, the need for storage of food 
and body shape and size (Kararli, 1995). 
 2.1.1.1 Mouth and Stomach  
 The digestion of carbohydrates is minimal in the stomach, but before food enters the 
stomach, it is partially broken down in the mouth. For example, starch digestion first begins in 
the mouth when it is broken down through mastication and salivary amylase and is then moved 
in the form of a bolus to the stomach, where salivary amylase is still active in the stomach within 
the  boluses of food (Lentle & Janssen, 2011). Gastric juices containing hydrochloric acid (HCl) 
and the proteolytic enzyme pepsin are secreted into the stomach for protein digestion (Walthall et 
al., 2005).  
 The food is stored in stomach while it is digested and then released into the small intestine 
(Walthall, Cappon, Hurtt, & Zoetis, 2005). Before leaving the stomach there is sifting of the 
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stomach contents and a mixture of starch is passed into the small intestine, while larger particles 
stay in the stomach for further digestion (Lentle & Janssen, 2011).  
The microanatomy of the stomach consists of an epithelial lining and is folded into 
structures called rugae, and the lining also has depressions known as gastric pits, which contain 
gastric glands (Walthall et al., 2005). These gastric glands secrete the gastric juice into the 
stomach to help with digestion (Walthall et al., 2005). Rodent stomachs have a glandular and a 
non-glandular section (Kararli, 1995). The non-glandular section has thin walls and is involved 
in the storage and digestion of food (Kararli, 1995). In comparison, the glandular section has 
thicker walls and contains cells that secrete mucus, pepsinogen and HCl (Kararli, 1995). Another 
function of this organ is to get food ready for digestion and absorption in the small intestine 
(Ramsay & Carr, 2011). To mix and move the food into the small intestine it contracts due to the 
presence of three layers of smooth muscle; longitudinal, circular and oblique muscle. This 
contraction is important in that it provides a churning action needed for digestion (Walthall et al., 
2005), while liquid digested substances readily travel from the stomach to the small intestine 
(Ramsay & Carr, 2011).  
2.1.1.2 Small Intestine 
 The function of the small intestine is to further breaks down food and absorb nutrients 
(Walthall et al., 2005). This is aided by the pancreas, which secretes pancreatic amylase for 
carbohydrate digestion in the small intestine (Walthall et al., 2005). The smaller particles are 
mixed with the pancreatic amylase in the lumen of the intestine, which hydrolyzes a-1,4 
glycosidic bonds of amylose and amylopectin but not the a-1,6 glycosidic bonds of amylopectin 
(Lentle & Janssen, 2011). These end products are then depolymerized into glucose by 
oligosaccharides, including a-sucrase, lactase, b-galactosidase and others (Lentle & Janssen, 
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2011). Proteins are also digested in the small intestine into amino acids via pancreatic enzymes 
and enzymes on the brush border of enterocytes in the small intestine (Lentle & Janssen, 2011). 
However, proteins are not the focus of this study. Fats are also digested here, through the action 
of enzymes, and this will be discussed further in Section 2.3 Lipid Metabolism.   
Anatomically, the small intestine is divided into three sections, the duodenum, jejunum, and 
ileum (Mosenthin, 1998). The duodenum is the upper portion of the small intestine, attached to 
the pyloric end of the stomach (Walthall et al., 2005). The pancreatic duct and the common bile 
duct enter into the duodenum (Walthall et al., 2005). On the other end, the duodenum is 
connected to the jejunum, which is connected to the ileum or the terminal portion (Walthall et 
al., 2005). The function of the duodenum is to continually decompose food, including 
carbohydrates, using enzymes secreted from the pancreas and bile from the liver (Walthall et al., 
2005). 
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Figure 2.1: Mouse Small Intestine. Adapted from (Stephens, Tanianis-Hughes, Higgs, 
Humphrey, & Warhurst, 2002).  
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The large surface area of the small intestine  makes it highly efficient at the absorption of 
nutrients present to it (Kararli, 1995). Together the jejunum and ileum are responsible for 
absorption of nutrients, such as glucose, into the systematic circulation (Walthall et al., 2005). 
Villi cover the luminal surface of the small intestine and have many enterocytes on their surface, 
that function in absorption (Kararli, 1995). The enterocytes contain projections called microvilli 
(Kararli, 1995). This helps to facilitate efficient digestion and absorption of nutrients, including 
glucose (Walthall et al., 2005).  
Previously, the small intestine was regarded as an organ that regulates nutrient digestion 
and absorption (Breen, Rasmussen, Cote, Jackson, & Lam, 2013). However, it is now known that 
the duodenum can identify an influx of nutrients and stimulate negative feedback loops to block 
glucose production and the intake of food to regulate metabolic homeostasis (Breen et al., 2013). 
As well, nutrient sensing in the duodenum is impaired in obesity and diabetes, which is thought 
to contribute to elevated glucose production, as they cannot decrease food intake or production 
of glucose (Breen et al., 2013).  
2.1.1.3 Large Intestine 
 The large intestine is connected to the small intestine via the ileocecal junction (Walthall 
et al., 2005). The functions of the large intestine are water, mineral, Na and electrolyte 
reabsorption, waste product and toxic substance excretion, and is an environment for microbiota 
fermentation (Kararli, 1995; Mosenthin, 1998). Little digestion and absorption of carbohydrate, 
protein, and fat occurs here. The colon has the greatest amount of microorganisms which ferment 
nutrients, including carbohydrates (Kararli, 1995). Products of fermentation are volatile fatty 
acids which are absorbed in the distal portions of the intestine, through either a sodium 
independent or sodium-coupled monocarboxylate transporter family members, MCT and 
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SMCT’s, respectively. Major gene candidates include SMCT1 (SLC5A8), as well as MCT1 
(SLC16A) (Ganapathy et al., 2008; Gill et al., 2005; Halestrap & Meredith, 2004; Iwanaga, 
Takebe, Kato, Karaki, & Kuwahara, 2006; Kararli, 1995). Overall the large intestine has a 
greater diameter than the small intestine but is shorter in length (Walthall et al., 2005). The 
mucosa does not have any villi, which differs from the small intestine (Kararli, 1995). There is a 
large proportion of goblet cells, which produce mucous to facilitate transport through the lumen 
of the large intestine (Walthall et al., 2005).  
 2.1.1.4 Liver and Pancreas 
 The two accessory organs that help with digestion are the liver and pancreas. The liver is 
an exocrine gland that secretes bile for fat digestion, and detoxifies nutrients (Walthall et al., 
2005). This organ plays a role in nutrient metabolism processes, such as gluconeogenesis, urea 
synthesis and fatty acid oxidation (Mitra & Metcalf, 2012). It is separated by a septum of 
connective tissue into a left and a right lobe (Walthall et al., 2005).  
The second accessory organ, the pancreas, acquires both exocrine and endocrine function 
(Kim & Hebrok, 2001). The endocrine portion is made of pancreatic islets, known as the islets of 
Langerhans (Walthall et al., 2005). The beta (b) and alpha (a) cells of the islets of Langerhans 
secrete insulin and glucagon, respectively (Walthall et al., 2005). Insulin decreases blood glucose 
levels and glucagon increases blood glucose levels. The Y cells produce somatostatin and the PP 
cells produce pancreatic polypeptide (Kim & Hebrok, 2001). Somatostatin inhibits gastric 
secretions and pancreatic polypeptide modulates secretions of the pancreas. The exocrine portion 
has exocrine cells arranged in a grape-like structure that secrete enzymes through a series of 
ducts, which join with the pancreatic duct. It consists of acinar and duct cells and makes up 95-
99% of the pancreas (Kim & Hebrok, 2001). The pancreatic duct extends along the pancreas and 
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enters the duodenum (Walthall et al., 2005). The right and left hepatic ducts of the liver form the 
common hepatic duct, which links with the gallbladders cystic duct located on the outer surface 
of the liver (Walthall et al., 2005). Together, the common hepatic duct and the cystic duct form 
the common bile duct (Walthall et al., 2005). The common bile duct and the pancreatic duct link 
together at the duodenal papilla and empty into the duodenum, where digestion of fat, 
carbohydrates and proteins occur (Walthall et al., 2005). After digestion of carbohydrates in the 
duodenum, via pancreatic amylase and apical brush border sucrase, glucose is absorbed in the 
ileum and jejunum.  
2.1.2 Segmental Differences in Glucose Transporters and Absorption. After digestion 
of carbohydrates, glucose is absorbed through transporters, that have different gene expression 
levels and affinities in different segments of the intestine. It is known that in the porcine ileum, 
electrogenic ion transport induced by glucose is higher in the ileum compared to the jejunum 
(Klinger et al., 2018). It is also shown in mammals that there is little glucose absorption in the 
colon (Kararli, 1995).  
Thus far, sodium glucose co-transporter 1 (SGLT1/SLC5A1) and sodium glucose co-
transporter 2 (SGLT2/SLC5A2) are the most highly associated with active glucose transport 
using a concentration gradient in the intestine, and their functions will be described in greater 
detail in Section 2.1.3 Glucose Transporters. In many species, SGLT1(SLC5A1) has been found 
to be expressed greatly in the jejunum compared to the ileum (Herrmann et al., 2012). In mice, 
SGLT1 (SLC5A1)  and glucose transporter 2 (GLUT2/SLC2A2) gene expression was found 
along the small intestine and was greatest in the proximal sections (Yoshikawa et al., 2011). 
GLUT2 transports glucose in an energy-independent manner and will also be described fully in 
Section 2.1.3 Glucose Transporters. In addition, the protein content of SGLT1 (SLC5A1) was 
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greater in the jejunum compared to the duodenum or ileum in the intestine of rats (Balen et al., 
2008). In a study characterizing the transporter expression in porcine small intestine, the 
expression of SGLT1 (SLC5A1) and GLUT2 (SLC2A2) were both were decreased in the 
duodenum and distal ileum (Klinger et al., 2018). SGLT1(SLC5A1) was phosphorylated at 
serine 418 (pSGLT1/SLC5A1), and pSGLT1 (SLC5A1) expression was lower in the ileum 
compared to the jejunum (Klinger et al., 2018). The phosphorylation of SGLT1 (SLC5A1) could 
be a structural change, which occurs to adjust for conditions that decrease glucose transport, such 
as changes in the apical membrane potential, but are unrelated to the higher glucose transport in 
the ileum (Klinger et al., 2018). This means that the phosphorylation likely does not influence 
the differences in glucose transport in the jejunum and ileum, but is associated with it (Klinger et 
al., 2018). In comparison, SGLT2 (SLC5A2) has a higher expression in the distal mammalian 
intestine, but less information is known about this (Wood & Trayhurn, 2003). This difference in 
gene expression and phosphorylation events may partially explain the two kinetic transport 
systems found in the intestine. 
Two kinetic systems for sodium dependent glucose transport have been consistently 
found in the intestine of different species. For example, in jejunal brush border membrane 
vesicles of rabbit, two transport systems were found (Dorando & Crane, 1984). The first had a 
low affinity for glucose and an approximate Vmax of 28mmol/min and Km of 4mM (Dorando & 
Crane, 1984). The second system had a high affinity for glucose and values around 17mmol/min 
for Vmax and 0.05mM for Km (Dorando & Crane, 1984). As well, two systems of Na dependent 
transport were found in intestinal brush border membrane vesicles of cats (Wolffram, 
Eggenberger, & Scharrer., 1989). These include system 1(major), which was found to be a lower 
affinity and higher capacity for glucose, and system 2 (minor) was found to have a higher 
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affinity and lower capacity for glucose (Wolffram et al., 1989). This is because System 1 had 
higher Vmax than system 2, by 2.5 fold and a higher Km than system 2, by 5 fold (Wolffram et 
al., 1989). In addition, it was similarly found that glucose transport in bovine jejunal brush 
border vesicles occurred by diffusion, a major sodium-dependent system (low affinity) and a 
minor sodium-dependent system (high affinity) (Kaunitz & Wright, 1984).  
Additionally, these kinetic systems seem to have strong anatomical segmental 
segregation. Different species have segregation in Vmax (saturation of transporter) and Km 
(affinity for transporter) in the segments of the small intestine. In pigs, the mean Vmax in the 
ileum of weaned 5 month old pigs was 2-fold greater than the mean Vmax in the jejunum, in 
brush border membrane vesicle experiments (Herrmann et al., 2012). As well, the pig jejunum 
had a slightly greater Km (lower affinity) than the ileum but this difference was not significant 
(Herrmann et al., 2012). Similarly, two other independent studies found higher total change in 
glucose stimulated short circuit current in the ileum vs jejunum in pigs (Klinger et al., 2018; Von 
Heimendahl, Breves, & Abel, 2010). However, this seems to vary at weaning with pigs under 30 
days of age, with a greater capacity for glucose absorption is observed in the proximal small 
intestine (Moran et al., 2010; Puchal & Buddington, 1992). Another example of segmental 
differences in kinetics is an in situ intestinal perfusion experiment using a permeability-index 
approach measuring radiolabeled removal of glucose in rat ileum and jejunum. The results differ 
from the above studies in adult pigs mentioned in that the jejunum had a Vmax that was 2 times 
greater than in the ileum (Wang, Aum, & Francis, 1997). In addition, the Km was higher in the 
ileum compared to the jejunum (Wang et al., 1997). However, sodium dependence was not 
demonstrated. Similarly, jejunum and ileum brush border membrane vesicles of horses, had a 
higher value for Vmax than in the jejunum than in the ileum (Dyer et al., 2002.). Additionally, 
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the differences in the rate of glucose absorption at a single concentration of glucose between 
intestinal segments has been shown in multiple species, with noted differences during maturation 
of the animal (Buddington, 1992; Buddington & Diamond, 1990; Buddington & Diamond, 1992; 
Diamond, Karasov, Cary, Enders, & Yung, 1984). Supporting segmental differences in kinetics 
systems, even though Km and Vmax were not determined to identify the kinetic systems 
involved.  Thus, there seem to be significant differences both in age and species in the 
segregation of the kinetics. Additionally, these Km and Vmax and rates can be modified by diet 
as seen as seen in mice when carbohydrates in the diet are modified or in disease such as diabetes 
(Csaky & Fischer, 1981; Diamond et al., 1984).  Nonetheless, these differences in kinetics are 
thought to be due to differences in the expression or modification of the SGLT family members. 
The affinities (Km) and capacities (Vmax) for some of the SGLT transporters have been 
generally characterized allowing association between observed Km and Vmax’s in each 
intestinal segment and SGLT transporter (Wright, Hirayama, & Loo, 2007). The known Vmax 
for SGLT1 and SGLT2 is 4 nmol/min/mg protein and 10 nmol/min/mg protein, respectively 
(Brown, 2000). The known affinities or Km for glucose are 0.5mM for SGLT1 (SLC5A1), 2mM 
for SGLT2 (SLC5A1), and 2.4mM for SGLT4 (SLC5A9), 35mM for SGLT6 (SLC5A11) and 
greater than 30mM for SMIT1 (SLC5A3) (Wright et al., 2007). It has been postulated that the 
expression of SGLT1 (SLC5A1) in the jejunum, and SGLT2 (SLC5A2) in the distal tissues is 
thought to be partially responsible for the differences in segmental differences in kinetics (Balen 
et al., 2008; Wood & Trayhurn, 2003). Alternatively, modification of SGLT1 via 
phosphorylation has also been proposed to be associated with this difference (Klinger et al., 
2018). However, the rate differences of glucose absorption along the intestine of the of the 
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mouse has not been paired with specific Km or Vmax values, or SGLT gene expression to 
identify transporters involved (Diamond et al., 1984). 
2.1.3 Glucose Transporters. Glucose transporters are proteins that facilitate the 
transport glucose and other sugars across cell membranes (Table 1). As mentioned above, these 
transporters are essential to move glucose from the small intestine lumen into blood, but also for 
the blood into other tissues once they enter the blood. There are two families of glucose 
transporters that cells use to take up glucose from the extracellular fluid (Zhao & Keating, 2007). 
In studies involving mice and human intestines, monosaccharide transport was regulated by Na-
driven glucose co-transporters (SGLTs) and glucose transporters (GLUTs) (Ritze et al., 2014). 
However, the focus of this study is Na dependent glucose transport. The glucose transporter 
family solute carriers SLC2A (protein symbol GLUT), facilitates a bidirectional process of 
glucose transport that is energy-independent (Wright, 2013; Zhao & Keating, 2007). Whereas, 
the Na/glucose cotransporter family, solute carriers SLC5A (protein symbol SGLT) facilitate 
Na+-linked transport process against an electrochemical gradient, or active transport (Wright, 
2013; Zhao & Keating, 2007). There is evidence suggesting that all cotransporters, from all 
different gene families work in the same way and the transport occurs in an ordered manner 
(Wright, 2013). Both the direction and the rate of transport is dependent on the concentrations of 
the ligands found on each side of the membrane and the voltage of the membrane (Wright, 
2013).  
2.1.3.1 SGLT1 (SLC5A1) 
There are 12 members of the SGLT or SLC5A family (Wright, 2013). Some of the 
members of this family have been well characterized to transport sugar molecules, whereas 
others have not (Chen et al., 2010). The family members SGLT1-6 have been best characterized 
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in their ability to transport glucose transport and/or are found in the small intestine, and of these 
transporters, SGLT1(SLC5A1) and SGLT2 (SLC5A2) are the most well studied. Therefore, this 
review will focus mostly on these transporters.  
SGLT1 (SLC5A1) is often seen as the rate-limiting step for the entry of glucose into the 
body as they have been well characterized in the brush border membrane of enterocytes (BBM) 
(Batchelor et al., 2011; Wright, 2013). It is essential for the delivery of glucose and glucose 
homeostasis (Batchelor et al., 2011). However,  in addition to being found in the small intestine, 
it has also been characterized in the trachea, kidney, heart, brain, testes, prostate (Wright, 2013). 
Nonetheless, in the intestine of species, such as rats and pigs, this transporter has been shown to 
be more highly expressed in the jejunum than in the ileum (Balen et al., 2008; Herrmann et al., 
2012). It has a low capacity and high affinity for glucose (Ritze et al., 2014). The transport 
activity is activated when sodium binds extracellularly to the transporter site (Baud et al., 2016). 
This alters the transporters molecular confirmation, which allows the hexose-binding domain to 
become available (Baud et al., 2016). Hexoses that fit this domain bind to it and promote 
translocation of both the sodium and hexose into the cytosol (Baud et al., 2016). The dietary 
regulation of SGLT1(SLC5A1) expression and BBM glucose transport involves sensing by an 
intestinal sweet receptor (T1R2/T1R3 heterodimer) in intestinal enteroendocrine cells (Batchelor 
et al., 2011). It is known that the expression of SGLT1 (SLC5A1) in the intestine is regulated by 
sweet taste receptors on the membrane of enterocytes in the duodenum and jejunum (Baud et al., 
2016). Therefore, glucose found in the lumen modulates its transport by activating sweet taste 
receptors and increasing SGLT1 (SLC5A1) availability (Baud et al., 2016).  
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2.1.3.2 SGLT2 (SLC5A2) 
SGLT2 (SLC5A2), similarly to SGLT1 (SLC5A1) is also responsible for glucose 
transport across cells, using the sodium gradient created by sodium-potassium-ATPases (Jurczak 
et al., 2011). This transporter is found mostly in the kidney, brain, liver, heart muscle, thyroid 
and salivary glands have a low affinity and high capacity for glucose (Jurczak et al., 2011; 
Wright, 2013). It has also been shown to be expressed the distal intestine of mammals (Wood & 
Trayhurn, 2003). This may account for some of the segmental differences described in the above 
section, 2.1.2 Segmental Differences in Glucose Transporters and Absorption. SGLT2 (SLC5A2) 
is a protein that plays a role in glucose reabsorption in the kidney, and it is known to be highly 
expressed in the kidney cortex, and on the brush border membrane of cells in the proximal tubule 
(Chen et al., 2010; Vallon et al., 2011). SGLT2(SLC5A2) is similar to SGLT1 (SLC5A1) in that 
they share approximately 45% to 75% of the same protein sequence (Chen et al., 2010). 
However, biophysical experiments of human SGLT2 (SLC5A2) show great differences in 
function from human SGLT1 (SLC5A1) (Hummel et al., 2011). The Na to glucose coupling 
coefficient is 1 for SGLT2 (SLC5A2) and 2 for SGLT1 (SLC5A1), which indicates that SGLT2 
(SLC5A2) has a lower power stroke compared to SGLT1 (SLC5A1) (Wright, 2013).  
2.1.3.3 SGLT3-6 
There is little information regarding SGLT3 (SLC5A4), SGLT4 (SLC5A9), SGLT5 (SLC5A10), 
and SGLT6 (SLC5A11) and their affinities and capacities. In humans, SGLT3 (SLC5A4) is 
known to not transport glucose, however, the sugar depolarizes the plasma membrane is a 
saturable, Na-dependent and phlorizin sensitive manner (Bianchi & Diez-Sampedro, 2010; Diez-
Sampedro et al., 2003; Voss, Diez-Sampedro, Hirayama, Loo, & Wright, 2007). In mice, SGLT3 
(SLC5A4)  is said to transport sugar, however it has a low sugar affinity and uncoupled 
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stoichiometry when compared to SGLT1 (SLC5A1) (Diez-Sampedro & Barcelona, 2011). 
Suggesting that SGLT3 (SLC5A4) functions more as  a glucose sensor in mice (Diez-Sampedro 
& Barcelona, 2011). However, in pigs, SGLT3 (SLC5A4) has been defined as a low affinity, 
sodium-dependent glucose transporter and was originally mischaracterized as pig SGLT2 (Diez-
Sampedro, Lostao, Wright, & Hirayama, 2000). In addition to the intestine epithelium, it is found 
in cholinergic neurons in the enteric nervous system and neuromuscular junction, small intestine, 
skeletal muscle, kidney, uterus and testis (O’Malley, Reimann, Simpson, & Gribble, 2006). 
SGLT3 (SLC5A4) was also expressed in rat hypothalamic neurons and it is suggested that the 
protein may be involved in glucose sensing (Scheepers et al., 2004; Wright, 2013).  
In the intestine, kidney and liver, SGLT4 (SLC5A9) is a mannose transporter (Tazawa et 
al., 2005). It was also found to transport glucose in COS-7 cells, however with a lesser affinity 
than mannose (Wright, 2013). It’s physiological role has been suggested to help maintain 
mannose homeostasis (Tazawa et al., 2005). 
SGLT5 (SLC5A10) is a thyroid iodide transporter (Scheepers et al., 2004), but has also 
been shown to be a sodium-dependent sugar transporter (Grempler et al., 2012). It has a high 
affinity as well as capacity for both mannose and fructose, compared to glucose and galactose 
(Wright, 2013). The gene is primarily expressed in the human kidney cortex (Grempler et al., 
2012).  
SGLT6 (SLC5A11), also known as SMIT2 transports inositols instead of glucose in L6 
cell lines (Lin, Ma, Fitzgerald, & Ostlund, 2009). This transporter has a higher affinity for 
myoinositol, indicated by a low Km of 0.12mM, compared to a Km of 35mM for glucose 
(Wright et al., 2007). Of all the SGLTs, it has the lowest identity with human SGLT1 (SLC5A1), 
approximately 50% (Lin et al., 2009). It is expressed all over the human body, including the 
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intestine (Roll et al., 2002). In rabbits, this transporter was found to be primarily a Na-
myoinositol (carboxylic sugar) cotransporter (Wright, 2013). Additionally, in humans it was 
shown that SGLT6 (SLC5A11) may play a role as an autoimmune modifier gene (Tsai et al., 
2008). 
2.1.3.4 Other Contributing SLC5A Transporters  
These transporters are all sodium dependent but have either no affinity or poor affinity 
for glucose. NIS (SLC5A5) is a Na/iodine transporter in the thyroid gland (De La Vieja, Dohan, 
Levy, & Carrasco, 2000; Van Sande et al., 2003). SMVT (SLC5A6) is widely distributed and 
transports biotin, lipoate, panthothenate, and is also a Na/iodine transporter (De Carvalho & 
Quick, 2011). CHT1 (SLC5A7) is found in the central nervous system and transports Na/choline 
(Apparsundaram, Ferguson, & Blakely, 2001; Okuda & Haga, 2000; Okuda et al., 2000 ). 
SMCT1 (SCL5A8) and SMCT2 (SLC5A12) are widely expressed and are Na/monocarboxylate 
cotransporters, that transport lactate, pyruvate and nicotinate (Coady, Wallendorff, Bourgeois, 
Charron, & Lapointe, 2007; Gopal et al., 2007; Miyauchi, Gopal, Fei, & Ganapathy, 2004). 
SMIT1 (SLC5A3) is known as a Na/myoinositol cotransporter and is also suggested to transport 
glucose (Berry et al., 1995. ; Wright, 2013). However, because there is little known about these 
transporters and none are found in the small intestine, except for SMCT1(SCL5A8) and SMCT2 
(SLC5A12), they were not investigated in this study. 
2.1.3.5 Sodium Independent Glucose Transporters 
There have been 13 isoforms of GLUT identified (Karnieli & Armoni, 2008). There are 
three classes of GLUT’s, based on sequence similarities between the transporters. Class I or the 
glucose transporters, consists of GLUT1 (SLC2A1), GLUT2 (SLC2A2), GLUT3 (SLC2A3), and 
GLUT4 (SLC2A4) (Joost & Thorens, 2009). Class II consists of the fructose transporter, GLUT5 
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(SLC2A5) and GLUT7 (SLC2A7), GLUT9 (SLC2A9)  and GLUT11 (SLC2A11) (Joost & 
Thorens, 2009). Class III, includes GLUT6 (SLC2A6), GLUT8 (SLC2A8), GLUT10 
(SLC2A10), GLUT12 (SLC2A12) and HMIT1. In addition to class I, HMIT1, GLUT6 
(SLC2A6), GLUT8 (SLC2A8) and GLUT11 (SLC2A11) are suggested to be a sugar transporters 
as well (Joost & Thorens, 2009). GLUT1 (SLC2A1)  initiates glucose uptake into erythrocytes 
and GLUT2-5 (SLC2A2-5) are responsible for hexose transport into cells (Joost & Thorens, 
2009). However, this review focuses on members of the GLUT family that are well studied and 
transport glucose in the small intestine of animals, GLUT2 (SLC2A2) and GLTU4 (SLC2A4).  
2.1.3.6 GLUT2 (SLC2A2) 
 Glucose transporter-2 (GLUT2/SLC2A2) is a membrane bound protein that facilitates 
glucose diffusion through cell membranes in pancreatic β cells, liver, small intestine and the 
kidney (Zini et al., 2009). The mechanism for glucose diffusion by GLUT2 (SLC2A2) in 
epithelial cells involves SGLT1 (SLC5A1). When glucose concentrations are high, there is an 
inward flux of sodium (Na) ions via SGLT1 and this depolarizes the membrane and causes 
calcium (Ca) influx (Karasov & Douglas, 2013). This influx of Ca causes phospholipase to 
generate diacylglycerol and this then activates protein kinase C (Karasov & Douglas, 2013). As a 
result, there is reorganization of the cytoskeleton and proteins, including GLUT2 (SLC2A2), 
gain access to the apical membrane (Karasov & Douglas, 2013). This transporter has a high 
capacity uptake of glucose and fructose (Karasov & Douglas, 2013). It is also required for 
glucose-stimulated insulin secretion in β cells (Thorens, 2015).  
2.1.3.7 GLUT4 (SLC2A4) 
Glucose transporter-4 (GLUT4/SLC2A4) is expressed mainly in insulin sensitive tissues, 
such as myocytes and adipocytes (Zini et al., 2009). The GLUT4 (SLC2A4) transporter is 
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responsible for conducting insulin-induced glucose uptake (Vargas et al., 2004). Insulin 
stimulates the rapid translocation of GLUT4 (SLC2A4) from an intracellular pool to the plasma 
membrane of cells (Vargas et al., 2004). GLUT4 (SLC2A4) is highly regulated at protein and 
mRNA levels (Karnieli & Armoni, 2008). When the body is in a state of increased metabolic 
demands, glucose metabolism and GLUT4 (SLC2A4) expression are increased (Karnieli & 
Armoni, 2008). To compare, individuals with insulin resistance, in type 2 diabetes or obesity, 
regulation of GLUT4 (SLC2A4) mRNA gene expression and function is decreased (Karnieli & 
Armoni, 2008). 
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Table 2.1: Location and function of SGLT family glucose transporters. Adapted from (Wright, 
2013).  
Gene name Protein name Substrates Distribution 
 
SLC5A1 
 
SGLT1 
 
Glucose, galactose 
 
Small intestine, 
trachea, kidney, heart, 
brain, testes, prostate 
 
SLC5A2 
 
SGLT2 
 
Glucose 
 
Kidney, brain, liver, 
heart muscle, thyroid 
and salivary glands 
 
SLC5A4 
 
SGLT3 
 
Na, H 
 
Small intestine 
(cholinergic neurons), 
skeletal muscle, 
kidney, uterus and 
testis 
SLC5A9 SGLT4 Mannose, fructose, 
glucose 
Kidney, small 
intestine, brain, liver, 
heart, uterus, lung 
 
SLC5A10 
 
 
SGLT5 
 
Mannose, fructose, 
glucose 
 
Kidney cortex 
 
SLC5A11 
 
SGLT6/SMIT2 
 
Myoinositol, chiro-
inositol 
 
Thyroid, brain, heart, 
muscle, spleen, liver, 
lung 
SLC5A3 
 
SMIT1 Myoinositol (glucose) Brain, heart, kidney, 
lung 
SLC5A5 NIS I- Thyroid, lactating 
breast, colon, 
stomach and ovary 
SLC5A6 SMVT Biotin, lipoate, 
panthothenate, I- 
Brain, heart, kidney, 
lung, plasma 
SLC5A7 CHT Choline  Spinal cord, medulla 
SCL5A8 SMCT1 Short chain fatty 
acids 
Small intestine, 
kidney, brain, retina, 
muscle 
SLC5A12 SMCT2 Short chain fatty 
acids 
Intestine, brain, 
retina, muscle 
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Table 2.2: Location and function of GLUT family glucose transporters. Adapted from (Joost & 
Thorens, 2009).   
 
 
 
 
 
Gene name Protein name Substrates Distribution 
 
SLC2A1 
 
GLUT1 
 
Glucose 
 
Erythrocytes, brain 
SLC2A2 GLUT2 
 
Hexoses  
 
Liver, islets, intestine 
SLC2A3 GLUT3 
 
Hexoses  Brain 
SLC2A4 GLUT4 Hexoses Muscle, fat, heart, 
intestine 
SLC2A5 GLUT5 Hexoses Intestine, testis, 
kidney 
SLC2A6 GLUT6 
 
Sugars Spleen, leukocytes, 
brain 
SLC2A7 GLUT7 Unknown  Unknown  
SLC2A8 GLUT8 Sugars  Testis, blastocyst, 
brain 
SLC2A9 GLUT9 Sugars  Liver, kidney 
SLC2A10 GLUT10 Sugars  Liver, pancreas 
SLC2A11 GLUT11 Sugars Heart, muscle 
SLC2A12 GLUT12 Unknown  Heart, prostate 
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2.2 Carbohydrate Metabolism  
2.2.1 Glycolysis and Gluconeogenesis. Once glucose is absorbed across the intestinal 
epithelium it is transported throughout the body and metabolized or stored. Glucose is a common 
source of energy as most mammals use it to fuel their brains under normal conditions, and is the 
only fuel source that red blood cells can use (Berg, Tymoczko, Stryer, & Clarke, 2002). Dietary 
glucose is broken down in a process called glycolysis. Glycolysis is an anaerobic process and is a 
series of reactions that converts one molecule of glucose into two molecules of pyruvate and two 
molecules of ATP (Berg et al., 2002). Under anaerobic conditions, pyruvate is metabolized or 
fermented into lactate (Berg et al., 2002). Under aerobic conditions, glycolysis is more efficient, 
as pyruvate is oxidized into CO2 and more ATP is generated (Berg et al., 2002).  
Glucose can be produced in the body from non-carbohydrates in a process called 
gluconeogenesis (Berg et al., 2002). Non-carbohydrate precursors can either be converted into 
pyruvate and enter the pathway or enter the pathway at later stages as intermediates in the 
pathway, such as oxaloacetate or dihydroxyacetone phosphate (Berg et al., 2002). Non-
carbohydrate precursors can be lactate, amino acids, or glycerol. Amino acids are broken down 
from proteins in the diet and from proteins in skeletal muscle during times of starvation (Berg et 
al., 2002). Gluconeogenesis takes place mostly in the liver and the kidney to maintain blood 
glucose levels so that the brain and muscle tissues can uptake enough glucose (Berg et al., 2002). 
 Glycolysis and gluconeogenesis are similar pathways, with similar enzymes, but are not 
the reverse of each other (Berg et al., 2002). The exergonic and irreversible steps of glycolysis 
are bypassed in gluconeogenesis (Berg et al., 2002). Both pathways are highly regulated both 
hormonally and by internal cellular demand for glucose and do not occur at the same time in any 
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cell (Berg et al., 2002). Insulin, is central to hormonal regulation of glycolysis and 
gluconeogenesis is insulin. 
2.2.2 Role of Insulin and Insulin Signaling. The main role of insulin is to control the 
metabolism of carbohydrates, specifically glucose. It is secreted when there are high levels of 
glucose and amino acids circulating in the body, after an individual has consumed a meal (Pessin 
& Saltiel, 2000). Insulin is often referred to as the most anabolic hormone, it functions in tissue 
development, growth. However, it’s most pressing function is the maintenance of glucose 
homeostasis throughout the body (Pessin & Saltiel, 2000). This homeostasis includes a balance 
between glucose absorption in the intestine, production of glucose in the liver, and both uptake 
and metabolism in peripheral tissues (Saltiel & Kahn, 2001). In normal patients, glucose in the 
blood is maintained between 4-7mM through glucose homeostasis (Saltiel & Kahn, 2001). It is 
secreted by the pancreas, from the b cells found in the islets of Langerhans (Pessin & Saltiel, 
2000). Muscle and adipose tissue is where most of the glucose homeostasis takes place (Pessin & 
Saltiel, 2000). Insulin increases the uptake of glucose into these tissues (Pessin & Saltiel, 2000; 
Saltiel & Kahn, 2001) Clearance of circulating glucose from muscle and adipose is carried out 
through translocation of GLUT4 to the cell membrane, this translocation and gene expression is 
stimulated by insulin (Hernandez, Teruel, & Lorenzo, 2001; Pessin & Saltiel, 2000). Insulin 
reduces hepatic glucose output, by decreasing the processes of gluconeogenesis and 
glycogenolysis (Pessin & Saltiel, 2000). It also increases lipogenesis, protein and glycogen 
synthesis, and decreases lipolysis, and protein breakdown (Saltiel & Kahn, 2001). 
The receptor for insulin belongs to the subfamily of receptor tyrosine kinases, which are 
insulin-like growth factor receptor (IGF-I) and the insulin receptor-related receptor (IRR) (Saltiel 
& Kahn, 2001). These receptors consist of two a and two b subunits, which are tetrameric 
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proteins (Saltiel & Kahn, 2001). The two subunits act as allosteric enzymes, and when insulin 
binds to the a subunit, this causes the a subunit to inhibit the tyrosine kinase activity of the b 
subunit. This leads to transphosphorylation of the b subunits and a conformational change of the 
b subunits (Saltiel & Kahn, 2001). Now activated, the receptor will phosphorylate insulin 
receptor substrates (IRS), and other proximal substrates on tyrosine (Pessin & Saltiel, 2000). IRS 
protein phosphorylation of tyrosine establishes recognition sites for other effector molecules, 
such as type 1A phosphatidylinositol 3-kinase (PI 3-kinase) subunit (Pessin & Saltiel, 2000). PI 
3-kinase is the most important effector molecule as it is necessary for insulin stimulated glucose 
uptake through GLUT4 translocation (Pessin & Saltiel, 2000). It has been proposed that IRS and 
PI 3-kinase contact is crucial for PI 3-kinase interacting with GLUT4 vesicles (Pessin & Saltiel, 
2000). Serine/threonine kinase Akt (protein kinase B) and protein kinase C (PKC) act 
downstream of PI 3-kinase (Pessin & Saltiel, 2000). Akt and PKC result in an increase of 
glucose transport and GLUT4 localization to the plasma membrane (Pessin & Saltiel, 2000). 
These mechanisms of signaling intracellular GLUT4 vesicles to travel to the cell membrane are 
not well known (Pessin & Saltiel, 2000). GLUT4 is normally recycled between the cell 
membrane and the intracellular compartments (Pessin & Saltiel, 2000). Hormones, including 
insulin increase the mRNA levels of GLUT4 in skeletal muscle of teleost fish (Marin-Juez, Diaz, 
Morata, & Planas, 2013). Insulin also stimulates the exocytosis of GLUT4, which is similar to 
exocytosis of synaptic vesicles (Pessin & Saltiel, 2000). Mainly, GLUT4 vesicles consist of v-
SNARE proteins (Pessin & Saltiel, 2000). These proteins are VAMP2 and VAMP3 and during 
GLUT4 vesicle translocation, they interact with their t-SNARE equivalents in the plasma 
membrane (Pessin & Saltiel, 2000). The interactions with SNARE are important, but have not 
been shown to be a direct focus of insulin action (Pessin & Saltiel, 2000).  
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2.2.3 Insulin Effects on Glucose Transport and Metabolism. Insulin can alter glucose 
metabolism, indirectly, by changing free fatty acids produced from visceral fat, this is also 
known as the “single gateway” hypothesis (Saltiel & Kahn, 2001). For example, after a meal, 
insulin causes suppression of lipolysis in visceral fat, so triacylglycerols are produced in the 
visceral fat cells (Saltiel & Kahn, 2001). The produced triacylglycerols  travel through the portal 
vein to the liver, and the energy from which can increase glucose production (Saltiel & Kahn, 
2001). This sends a signal for insulin to be released, which can lead to insulin resistance in the 
liver, if insulin is constantly secreted to decrease the glucose in the blood  (Saltiel & Kahn, 
2001).  
Directly, insulin regulates the functions of a group of metabolic enzymes, via 
phosphorylation and dephosphorylation, and controls the gene expression of hepatic enzymes 
involved in gluconeogenesis and glycolysis (Pilkis & Granner, 1992). One of these enzymes is 
phosphoenolpyruvate carboxylase, and insulin blocks the transcription of this gene, which is the 
rate limiting step in gluconeogenesis (Sutherland, O’Brien, & Granner, 1996). In addition, 
insulin can lessen the transcription of the genes for fructose-1,6-bisphosphatase and glucose-6-
phosphatase and increase the transcription of the genes for glucokinase, pyruvate kinase 
(enzymes involved in glycolysis) and fatty acid synthase and acetyl-CoA carboxylase (enzymes 
involved in lipolysis) (Saltiel & Kahn, 2001). 
In addition to the above described effects on GLUT, insulin can also affect the transport 
of glucose through SGLT’s. The effect of insulin on SGLT1 and SGLT2 activity in HEK-293T 
cells was investigated by adding 100pM and 400pM of insulin (Ghezzi & Wright, 2012). At 
400pM, there was increased Na-glucose transport via SGLT2, but SGLT1 transport was 
unaffected (Ghezzi & Wright, 2012). 
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2.2.4 Development of Insulin Resistance. Insulin resistance develops in hyperglycemic 
states, which is when blood glucose levels are chronically high, such as in cases of obesity 
(Tomás et al., 2002). This is because insulin secretion and production is mediated by glucose 
(Scheepers et al., 2004). These high blood glucose levels result in increased glucose sensitivity, 
insulin secretion and a decrease of insulin stores, which leads to insulin resistance (Scheepers et 
al., 2004). In addition, cells that are insulin targets do not instigate normal insulin signaling, and 
are therefore resistant to insulin, which decreases glucose uptake and is the cause for the 
development of type 2 diabetes if this occurs long term (Chang, Ho, Lu, Huang, & Shiau, 2012; 
Martin et al., 1992 ). The disruptions in insulin signaling that are associated with insulin 
resistance are covered in more detail in Section 2.6.3 Insulin Resistance and Signaling.  
GLUT4 expression is also said to be important in the development of insulin resistance 
(Scheepers et al., 2004). Insulin is secreted, because of glucose in the blood, which stimulates the 
translocation of GLUT4 to the plasma membrane and an increase in glucose transport (Scheepers 
et al., 2004). If GLUT4 expression is decreased, tissues are not able to respond to insulin, 
especially in the muscle (Scheepers et al., 2004).  
 
2.3 Metabolic Diseases 
2.3.1 Obesity. The increased incidence of obesity in Western societies has caused an 
increase in health care burden and a decrease in life expectancy (Wang & Liao, 2012). Obesity 
involves decades of pathophysiological changes and is a complex and chronic disease (Wang & 
Liao, 2012). In 1998, obesity was characterized by the World Health Organization as excess 
body fat that has negative effects on health and well-being (Deurenberg, 2007). To define obesity 
in subjects, a BMI has been used, which measures body fat percentage and takes height into 
account (Deurenberg, 2007). For a person to be obese, the BMI cut off is suggested to be 
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>30kg/m2 (Deurenberg, 2007). However, the relevance of this cutoff is controversial as is it 
based off of studies in Europe and the United States only (Deurenberg, 2007).   
The development of obesity involves the combination of nutrition, metabolism and the 
immune system (Maioli et al., 2016). Imbalances in food intake, such as high carbohydrate diets, 
basal metabolism and energy expenditure all contribute to obesity (Maioli et al., 2016). 
Consumption of high carbohydrate and high fat diets change the metabolism and transport of 
these nutrients, as previously mentioned. There are multiple causes for these imbalances and 
therefore obesity, but the most common are excessive intake of calories and energy dense meals 
that are often consumed (Maioli et al., 2016). When rodents consume a high fat diet, they 
become insulin resistant, which is followed by ineffective compensation from the b cells, which 
leads to glucose intolerance (La Fleur et al., 2011). In these types of obese models, there are 
increased concentrations of free fatty acids and triglycerides in the body (La Fleur et al., 2011).  
Obesity is known to influence the development of other diseases including type 2 
diabetes, hypertension, insulin resistance, dyslipidemia, atherosclerosis, degenerative joint 
disorders, cancer and metabolic syndrome (Lee, 2013; Maioli et al., 2016). Metabolic syndrome 
onset is elevated with the degree  of obesity (Lee, 2013). It is included in the definition of pre-
diabetes which leads to type 2 diabetes (Grundy, 2012).  
2.3.2 Prediabetes. There is a group of patients who do not have glucose levels that meet 
the definition of diabetes, but are higher than normal (American Diabetes, 2010) and would be 
considered prediabetic. Previously mentioned, higher glucose levels can change the transcription 
of glucose transporter genes. These patients are recognized as having impaired fasting glucose 
(IFG) or  impaired glucose tolerance (IGT) (American Diabetes, 2010). IFG and IGT patients are 
defined as having pre-diabetes, and have a high risk for the onset of diabetes and cardiovascular 
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disease (American Diabetes, 2010). Therefore, these risk factors are intermediate processes in 
the development of diabetes and many other diseases (American Diabetes, 2010). Both IFG and 
IGT are linked to obesity, mainly abdominal obesity, dyslipidemia and hypertension (American 
Diabetes, 2010). Excess body fat, depressed glucose tolerance and insulin resistance are 
characteristic of prediabetes (Mayans, 2015). IFG patients have fasting plasma glucose levels of 
100 mg/dl (5.6 mmol/l) to 125 mg/dl (6.9 mmol/l) (American Diabetes, 2010). In comparison, 
patients with IGT have oral glucose tolerance test values of 140 mg/dl (7.8 mmol/l) to 199 mg/dl 
(11.0 mmol/l) (American Diabetes, 2010).  
2.3.3 Metabolic Syndrome and Dysfunctions. The prevalence of pre-diabetes and 
metabolic syndrome overlap, and metabolic syndrome is referred to as a pre-diabetic state 
(Grundy, 2012). People with metabolic syndrome have a 5-fold increase in developing diabetes 
than those without it (Grundy, 2012; La Fleur et al., 2011; Samson & Garber, 2014).  For people 
with IFG or IGT, the risk for diabetes is increased by 5 to 7-fold compared to normal patients 
(Grundy, 2012). Furthermore, the risk of diabetes is increased even more when a person has both 
pre-diabetes and metabolic syndrome (Grundy, 2012). Components of metabolic syndrome 
include increased glucose levels, abdominal obesity, increased blood pressure, increased 
triglycerides and decreased high-density lipoprotein cholesterol, insulin resistance, dyslipidemia 
and hypertension and is (Grundy, 2012; La Fleur et al., 2011; Saddoris, Gabler, Spurlock, & 
Radcliffe, 2007; Samson & Garber, 2014). If a patient displays any 3 of these components, they 
have metabolic syndrome (Grundy, 2012). One of the most common is abdominal obesity, extra 
adipose tissue produces excess fatty acids and adipokines that contribute to metabolic risk factors 
to diabetes and other diseases (Grundy, 2012). There is belief that insulin resistance modulates 
each of the metabolic risk factors of metabolic syndrome, as most people with metabolic 
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syndrome are insulin resistant (Grundy, 2012). To treat metabolic syndrome, changes in diet and 
exercise that result in weight loss are needed. There is also pharmacological treatment of 
atherogenic dyslipidemia, hypertension and hyperglycemia (Samson & Garber, 2014).  
Sugars in the diet can alter metabolism by modifying enteroendocrine cells (Ritze et al., 
2014). These cells are primary chemoreceptors and foundations of gastrointestinal hormones and 
peptides (Ritze et al., 2014). There is some evidence that shows a correlation between sugar 
absorption and the production and roles of some peptides (Ritze et al., 2014). Because of this, it 
is suggested that increases in sugar uptake and absorption that is seen in obesity, a component of 
metabolic syndrome, can enhance energy uptake, as well as change the sugar transport across the 
epithelium and alter the release of gastrointestinal hormones in the intestine (Ritze et al., 2014). 
This following work therefore investigated what causes these changes in sugar transport.  
2.3.4 Type 2 Diabetes. Globally, there is an increase in obesity and type 2 diabetes, 
which are associated with hypertension and cardiovascular diseases, and this is becoming a 
major health issue (Dhar et al., 2013). In the last 2-3 decades, this increase in type 2 diabetes has 
been a result of high carbohydrate diets and sedentary lifestyles (Dhar et al., 2013). People with 
type 2 diabetes have a risk for high blood pressure, that is four times greater than people without 
it (Dhar et al., 2013). In Western societies, there is a shift in preference to sugar-sweetened 
beverages and sugar-rich processed foods, and this shift is a major cause for obesity, as well as 
an increase in sedentary lifestyles (Ritze et al., 2014).  
Approximately 350 million people are affected by diabetes (Breen et al., 2013). Type 2 
diabetes is a metabolic disorder, defined by insulin resistance and diminished glucose transport 
throughout the body (Carvalho et al., 2013). Diabetes is characterized as hyperglycemia, due to 
defects in insulin secretion and/or action (American Diabetes, 2010). This chronic 
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hyperglycemia leads to long-term damage, dysfunction and failure of various organs, including 
the eyes, kidneys, nerves, heart and blood vessels (American Diabetes, 2010). The onset of 
diabetes is complex and said to involve many pathogenic processes (American Diabetes, 2010). 
Some of these processes are destruction of pancreatic b cells, leading to insulin resistance 
(American Diabetes, 2010). Also, dysfunctions in carbohydrate, fat and protein metabolism 
causes insufficient insulin action on target tissues (American Diabetes, 2010). Insufficient insulin 
action is also caused by poor insulin secretion or decreased tissue responses to insulin at one or 
more points in the insulin signaling pathway (American Diabetes, 2010). Both processes, 
dysfunctions of insulin secretion and insulin action usually occur in the same patient, therefore 
the cause of hyperglycemia is frequently unknown (American Diabetes, 2010).  
 Type 2 diabetes is caused by glucotoxic effects (high blood glucose), which include 
apoptosis of pancreatic β cells and gradual burnout of β cells (Hewson-Hughes et al., 2011). In 
addition, chronic levels of high blood glucose result in damaged insulin action through decreased 
insulin signaling (Merovci et al., 2014). Damaged insulin action impairs the ability of insulin to 
maintain glucose homeostasis in the body. When there are high levels of blood glucose, 
methylglyoxal production is increased (Dhar et al., 2013). Methylglyoxal is a reactive dicarbonyl 
which is produced during glucose and fructose metabolism (Dhar et al., 2013). It is involved in 
the generation of advanced glycation end products (AGEs) and decreases the activity of 
antioxidant enzymes, including glutathione reductase and glutathione peroxidase (Dhar et al., 
2013). This decreased activity causes oxidative stress, which is said to initiate the 
pathophysiological changes involved in diabetes, hypertension and aging (Dhar et al., 2013). 
This oxidative stress drives inflammation, impaired insulin signaling and changes in glucose 
transporters in the obesity models fed high sugar and high fat diets.  
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2.4 Models of Metabolic Disease 
2.4.1 High Sugar Diets. It has been proven that factors associated with diet are crucial in 
moderating the onset of enhanced adiposity and metabolic dysfunctions (Maioli et al., 2016). 
There is a link between the ingestion of beverages sweetened with sugar and saturated fat with 
obesity and diabetes (La Fleur et al., 2011). In the past few decades, the consumption of sugar-
sweetened drinks and saturated fat has increased and exceeds recommended daily levels (La 
Fleur et al., 2011). Diets high in refined carbohydrate cause acute and continual inflammation 
and metabolic abnormalities, not necessarily with elevated body weight (Maioli et al., 2016). It is 
important to know how eating high fat and sugar diets effect the onset of obesity and type 2 
diabetes (La Fleur et al., 2011). There have been studies conducted that provide evidence that 
changes in sugar signaling pathways, because of high sugar diets, impact feeding behavior, 
intestinal sweet taste receptors, sugar transporters, and weight-regulating gastrointestinal 
hormone expression (Ritze et al., 2014). 
 
2.4.1.1 High Sugar Foods 
High carbohydrate diets, consisting of mostly fructose corn syrup and sucrose are one of 
the main causes for obesity and type 2 diabetes (Dhar et al., 2013). Male Sprague-Dawley rats 
were fed a high fructose diet for four months (Dhar et al., 2013). The rats had a significant 
elevation of blood pressure, methylglyoxal levels in the aorta and kidney, and protein expression 
for the AGEs receptor (RAGE) (Dhar et al., 2013).   
In experiments with rats fed diets consisting of saturated fat alone, 30% sugar in drinking 
water alone, a combination of dietary fat plus sucrose in the drinking water or regular pellet 
chow, the development of obesity was investigated. The animals on each of these diets became 
quickly obese compared to the regular pellet chow which remained normal weight. Moreover, 
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after one week, the rats had elevated plasma glucose concentrations compared to regular chow-
fed rats, while insulin levels stayed the same (La Fleur et al., 2011). This is evidence for the 
onset of glucose intolerance and insulin resistance (La Fleur et al., 2011). In comparison, mice 
fed a solid pellet diet high in both sugar and fat had voluntary hyperphagia, fast weight gain, 
greater fat pad mass and were in a prediabetic state, defined by glucose and insulin intolerance 
(Maioli et al., 2016). Rats on either the solid high fat diet or the high sucrose drinking water 
combined with a standard chow became obese. In addition, the rats fed both the solid high fat 
diet and the high sucrose drinking water, and the rats fed the solid high fat diet alone, each had 
changes at the level of the hypothalamus (La Fleur et al., 2011). Neuropeptide Y expression was 
increased in the rats fed the high dietary fat in combination with sucrose in the drinking water 
and proopiomelanocortin expression decreased, these molecules control glucose metabolism, 
indicating glucose intolerance (La Fleur et al., 2011). The rats fed high dietary fat alone had 
opposite effects compared to the rats fed both the solid high fat diet and the high sucrose 
drinking water at the level of the hypothalamus (La Fleur et al., 2011). The rats fed only high 
sucrose drinking water with a standard chow had no changes at the hypothalamic level (La Fleur 
et al., 2011). These hypothalamic alterations may be a crucial regulator of diet induced changes 
in glucose metabolism (La Fleur et al., 2011). 
 
2.4.1.2 High Sugar Drinks  
Sucrose and fructose-rich soft drinks consumed with meals cause an increase in energy 
uptake, as these sugary drinks provide extra calories that people consume in addition to solid 
meals, which is a factor that can lead to obesity (Ritze et al., 2014). In a study, C57bl/6 mice 
were fed drinking water or solid high fructose and high sucrose diets for eight weeks, to 
investigate their effects on the development of obesity (Ritze et al., 2014). The mice that were 
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fed the high sucrose drinking water had an increase in total calories ingested, in comparison to 
the solid high sucrose diet and control (Ritze et al., 2014). Conversely, the mice fed the high 
sucrose drinking water had an increase in weight of 4.5g, whereas the mice fed the solid high 
sucrose had a weight gain of 3.8g (Ritze et al., 2014). The liquid high-sucrose diet also had 
elevated GLUT2 and GLUT5 expression in the ileum (Ritze et al., 2014).  
 Similar results were also found in humans. Humans that consume sugar sweetened 
beverages often have increases in weight gain and risks of obesity (Malik et al., 2010). In a meta-
analysis, it was found that subjects who drink 1-2 servings of sugar sweetened beverages each 
day, had an increased their risk of getting type 2 diabetes by 26%, when compared to subjects 
who drink these types of beverages at a minimum of 1 serving per month (Malik et al., 2010).  
In addition, an eight-year study was performed to investigate the link between ingestion 
of sugar sweetened beverages and weight changes and type 2 diabetes risks in women (Schulze 
et al., 2004). The results of this study also found that increased consumption of sugar sweetened 
beverages is linked to a vast increase in weight gain and chance of getting type 2 diabetes 
(Schulze et al., 2004). This is suggested to occur due to the extra calories and excess amounts of 
sugars in these beverages (Schulze et al., 2004). Also, the types of sugars that are in these 
beverages are absorbed rapidly (Schulze et al., 2004). 
There are still many unanswered questions about the function of sucrose and fructose in 
the development of obesity and other metabolic diseases (Ritze et al., 2014). This is partly since 
most studies have looked at short-term effects of sugars on metabolism and other various factors 
(Ritze et al., 2014). As well, there is a lot of evidence that shows the effects of obesity, which is 
caused by high fat or high sugar diets, however, there is not much evidence regarding the onset 
of metabolic or immune dysfunctions when animals are fed these types of diets, which mimic 
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classical Western diets of today (Maioli et al., 2016). The changes in Western diets are 
responsible for the great trend of obesity in humans (Maioli et al., 2016). In obesity caused by 
diet, it is still unknown if changes in glucose metabolism are directly because of adaptations to 
the diet or indirectly because of obesity (La Fleur et al., 2011). 
 
2.5 Regulation of Changes in Glucose Transporters  
2.5.1 Glucose transport & Obesity. When blood glucose is elevated due to a diet that is 
high in sugars or fats, the expression of intestinal glucose transporters is changed (Ritze et al., 
2014). It has been proposed that digestive system function adapts to diet content. For example, 
the gut adapts to the amount of carbohydrates, protein or fat by altering the number of enzymes 
and co-transporters present in response to macronutrient content of the diet (Karasov & Douglas, 
2013) 
Alternatively, in obesity, there is evidence for increased glucose absorption in the 
intestine (Baud et al., 2016). This is said to be related to an increase in SGLT1 expression in the 
proximal intestine (Baud et al., 2016). As well, in type 2 diabetics, the expression of SGLT1 in 
the duodenum was 3-4 times higher than in healthy people (Baud et al., 2016). This means that 
the increased capability for SGLT1-mediated glucose absorption in the intestine may be a factor 
contributing to impaired glucose metabolism, which can be caused by alterations in the diet 
(Baud et al., 2016). 
It has been suggested that absorption of nutrients in the intestine is quicker and more 
efficient in obese people, compared to lean people (Nguyen et al., 2015; Wisén & Johansson, 
1992). There is not much known about this topic, however, it has been proven that the increase in 
blood glucose after consumption of beverages containing carbohydrates was more elevated in 
obese patients than in lean patients (Seimon et al., 2013). The reason for this may be in part due 
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to insulin resistance characteristic to obesity, but could also be due to the increased and rapid 
intestinal glucose absorption (Nguyen et al., 2015). As confirmed by animal studies, the rapid 
glucose absorption is said to be modulated by the presence of luminal glucose through activation 
of sweet taste receptors in the intestine (Young, 2011; Young et al., 2009). Once the sweet taste 
receptors have been activated, they can increase the availability of SGLT1 and GLUT2 
(Gorboulev, Schürmann, & Vallon, 2012; Kellett & Brot-Laroche, 2005; Young et al., 2009). In 
mice that have been genetically modified and have a 7-fold increase in SGLT1 proteins, have an 
elevated rate of glucose absorption in the intestine and visceral obesity (Fujioka, Matsuzawa, 
Tokunaga, & Tarui, 1987; Osswald et al., 2005). However, there have not been many studies 
done to investigate changes in obese patients and their gene expression of sweet taste receptors 
or SGLT1 (Ait-Omar, Monteiro-Sepulveda, & Poitou, 2011).  
Biopsies from the duodenum were taken from control patients and patients with type 2 
diabetes (Dyer, Wood, Palejwala, Ellis, & Shirazi-Beechey, 2002). SGLT1 and GLUT5 protein 
levels were increased up to 3 or 4-fold in the diabetic patients compared to the control patients 
(Dyer et al., 2002). Also, brush border enzymatic activity and levels of sucrase and lactase were 
increased by two-fold, and GLUT2 and GLUT5 mRNA expression was increased by three-fold 
in the mucosa (Dyer et al., 2002). Therefore, it was suggested that in diabetic patients, there is a 
greater capacity for glucose and fructose absorption, which is because of an increase in 
expression of transporters (Dyer et al., 2002).  
When all this evidence is put together, it seems that intestinal sweet taste receptors and 
glucose transporters modulate glucose absorption, hyperglycemia and bodyweight (Nguyen et 
al., 2015). It is also suggested that elevated intestinal glucose absorption, due to increases of 
sweet taste receptors and/or glucose transporters in the intestine is related to obesity and type 2 
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diabetes (Nguyen et al., 2015). The increases in absorption of glucose in the intestine could 
possibly lead to the development of hyperglycemia, hyperinsulinemia, insulin resistance and 
lipogenesis (Nguyen et al., 2015). However, it is difficult to tell whether these changes are 
induced by obesity and diabetes, as described, or diet, which is known to impact expression of 
glucose transporters.  
2.5.2 Nutrient Effect on Transporters in Various Species. 
2.5.2.1 Pigs  
In an experiment with Ossabaw pigs fed a high fat diet, Na-dependent glucose uptake and 
SGLT1 expression in the jejunum were investigated (Saddoris et al., 2007). After 20 weeks on 
either the control or high fat diet, jejunal segments were placed in modified Ussing chambers 
(Saddoris et al., 2007). Short-circuit current was 55% lesser in high fat diet pigs compared to the 
control pigs (Saddoris et al., 2007). Na-dependent uptake of glucose was lower after the chronic 
consumption of high fat (Saddoris et al., 2007). The expression of SGLT1 in the jejunum was 
decreased in the pigs on the high fat diet compared to the control, but the difference was not 
considered significant (Saddoris et al., 2007). The results of this study conclude that the high fat 
diet caused a reduced Na-dependent glucose uptake, even though SGLT1 expression was 
unchanged in the jejunum (Saddoris et al., 2007).  
In another study, 28 day old piglets were weaned onto isoenergetic diets with varying 
amounts of carbohydrate to investigate the gene expression of SGLT1 in the small intestine 
(Moran et al., 2010). SGLT1 mRNA was unchanged when the pigs were fed up to 40% inclusion 
of carbohydrate (Moran et al., 2010). However, when the carbohydrate levels were included at 
>50%, there were significant increases in SGLT1 mRNA (Moran et al., 2010).  
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2.5.2.2 Horses 
Similarly, in horses fed increased amounts of hydrolysable carbohydrate (grain) and 
levels of glucose absorption were measured through intestinal SGLT1 (Dyer et al., 2009). The 
mRNA expression of SGLT1 was increased 2-fold in the jejunum and 3.2-fold in the ileum 
compared to the group of horses on pasture forage (Dyer et al., 2009).  
2.5.2.3 Rats and Mice 
Glucose transport is also impaired in other tissues, including muscle. It was found that 
glucose transport stimulated by muscle contractions is impaired in rodents fed high fat diets 
(Hansen et al., 1998). Skeletal muscle glucose transport is initiated by insulin or contractions, 
and is regulated by GLUT4 translocation to the plasma membrane (Hansen et al., 1998). It has 
been suggested that insulin resistance caused by high fat diets is modulated by reduced 
translocation of GLUT4 to the cell surface (Hansen et al., 1998). There is also evidence to prove 
that high fat diets cause reduced GLUT4 intrinsic activity in skeletal muscle (Hansen et al., 
1998). (Breen et al., 2013) 
Diets with increased levels of resistant starch have been shown to decrease the risks of 
obesity and diabetes (Cao et al., 2018). Pyrodextrin is similar to resistant starch and there is some 
interest in its use for treatment of obesity and diabetes, as a functional food (Cao et al., 2018). 
When given orally for seven weeks, to mice with high fat induced obesity, blood glucose levels, 
HbA1c, triglycerides, adipocyte size, and body weight were all decreased (Cao et al., 2018). In 
addition, SGLT1 and GLUT2 expression in the intestine were reduced to 70% and 60% 
compared to the control obese mice, respectively (Cao et al., 2018), resulting in decreased 
glucose transport into the blood and enhanced hepatic metabolism of glucose (Cao et al., 2018). 
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In mice, intestinal sleeves in vitro were used to determine the effects of carbohydrates in 
the diet on monosaccharide transport (Diamond et al., 1984). The first treatment group received a 
no carbohydrate diet (0% sucrose and 70% protein) and had similar glucose transport along each 
section of the small intestine (Diamond et al., 1984). However, the second treatment group that 
received the high carbohydrate diet (55% sucrose and 15% protein) had increased glucose 
transport in the ileum (Diamond et al., 1984). Therefore, it was shown that carbohydrates in the 
diet can cause changes in the presence of monosaccharide transporters along the intestine 
(Diamond et al., 1984). 
2.5.2.4 Cattle 
Expression of glucose transporters was also explored in calves fed either hay, concentrate 
or corn silage diets with milk replacer (Klinger, Noci, Müller, & Breves, 2013). In addition, the 
Na dependent glucose absorption and expression of SGLT1 was studied in jejunal brush border 
membrane vesicles (Klinger, Noci, et al., 2013). The glucose transport was highest for the 
concentrate and corn silage diets (Klinger, Noci, et al., 2013). However, the hay diet had the 
highest expression of SGLT1 protein (Klinger, Noci, et al., 2013).  
2.5.2.5 Goats 
Various starch sources were included in diets for goats to determine the adaptations of 
intestinal tissues when exposed to different diets (Klinger, Zurich, Schroder, & Breves, 2013). 
Three diets were fed, including hay, wheat-based concentrate and corn-based concentrate 
(Klinger, Zurich, et al., 2013). The jejunal tissue of the hay-fed goats had increased short-circuit 
current (Klinger, Zurich, et al., 2013). As well, the unidirectional flux rate of glucose was 
increased in the hay-fed animals (Klinger, Zurich, et al., 2013). Whereas the glucose transport 
into brush border membrane vesicles was increased in concentrate-fed goats, but the affinity and 
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expression of SGLT1 was unaffected (Klinger, Zurich, et al., 2013). Therefore, it is possible that 
SGLT1 glucose uptake is changed as a result of adaptation to different dietary starches (Klinger, 
Zurich, et al., 2013).  
The results of these studies are more evidence to suggest that the inclusion of different 
nutrients in the diet impact the expression of glucose transporters, in a variety of species. 
However, these studies mostly focus on SGLT1, GLUT2 and GLUT4 and there is a gap in the 
literature regarding the effects of nutrients on gene expression of the rest of the SGLT and GLUT 
families.  
2.5.3 Insulin Resistance and Signaling. Another factor affecting glucose absorption is 
the development of insulin resistance and impaired insulin signaling. Insulin resistance occurs 
when cells that are targets of insulin can no longer initiate insulin signaling properly, and become 
insensitive to insulin (Chang et al., 2012). This dysfunctional insulin signaling causes decreases 
in glucose uptake and increases in gluconeogenesis in the liver (Chang et al., 2012).There is 
evidence that insulin receptor substrates (IRS) play a part in the development of type 2 diabetes 
(Withers et al., 1998). Receptors for insulin and IGF1 initiate phosphorylation of IRS-1 and IRS-
2, which stimulate further pathways, including PI 3/Akt cascades (Hennige et al., 2003). Both 
insulin action and secretion are associated through IRS-2 in the insulin/IGF pathway (Hennige et 
al., 2003). IRS regulate signals that are prompted by insulin receptors and cytokines (Withers et 
al., 1998).  
Deficiencies in IRS-1 are said to not be involved in the development of type 2 diabetes, 
as insulin secretion is increased to counteract for the slight resistance to insulin (Withers et al., 
1998). In experiments with homozygous IRS-1 knockout mice, these animals develop a slight 
state of insulin resistance and impaired growth, but are not diabetic (Pessin & Saltiel, 2000; 
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Saltiel & Kahn, 2001). This is thought to be due to compensation of the b cells (Hennige et al., 
2003; Pessin & Saltiel, 2000). Similarly, mice with knockouts for IRS-3 or IRS-4 do not exhibit 
insulin resistance and have normal growth (Fantin, Wang, Lienhard, & Keller, 2000).  
However, IRS-2 deficiency is shown to disrupt both the function of pancreatic b cells and 
insulin signaling (Withers et al., 1998). With homozygous knockout of IRS-2, there is an 
impairment in insulin secretion, insulin resistance in peripheral tissues and liver, decreased 
growth in some regions of the brain, islets and retina and diabetes (Pessin & Saltiel, 2000; Saltiel 
& Kahn, 2001). In these mice, insulin resistance as well as the decreased growth of the β cells 
leads to type 2 diabetes (Withers et al., 1998). In addition, mice that are IRS-2 deficient, have 
decreases in the mass of b-cells and decreased insulin secretion, leading to the onset of type 2 
diabetes (Hennige et al., 2003). As well, in IRS-2 deficient mice, there is an imbalance in 
glucose homeostasis due to insulin resistance in liver and skeletal muscle tissues (Withers et al., 
1998). There is also no counteraction from b cells for this insulin resistance (Withers et al., 
1998). Therefore, the role of IRS-2 in the insulin/IGF pathways is crucial for the function of β-
cells (Hennige et al., 2003).  
This role of IRS-2 insulin signaling and resistance was confirmed by the observation that 
chronic over-secretion of insulin suppresses mRNA expression of IRS-2 (Shimomura et al., 
2000). IRS-2 is known as a necessary part of the insulin signaling pathway in the liver 
(Shimomura et al., 2000). Therefore, decreases in gene expression of IRS-2 is a cause for insulin 
resistance (Shimomura et al., 2000).  
As well, adipocytes produce circulating free fatty acids (FFA) in insulin resistant states 
and may contribute to the insulin resistance characteristic to obesity and diabetes (Bergman & 
Ader, 2000). Increased FFAs have been known to decrease insulin-stimulated IRS-1 
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phosphorylation and IRS-1 associated PI 3-kinase activity, and cause accumulation of 
triglycerides in muscle and liver tissues (Saltiel & Kahn, 2001; Shulman, 2000). In experiments 
with transgenic mice that have increased triglyceride tissue content, have depressed insulin 
action and stimulation of IRS-associated PI 3-kinase (Kim et al., 2001).  
Additionally, studies of high fat diets are known to instigate resistance of glucose and 
insulin in skeletal muscle (Hansen et al., 1998). A study was developed to see if high fat diets 
cause changes in plasma membrane composition, which interfere with the functions of glucose 
transporters or insulin receptors (Hansen et al., 1998). Rats were fed a high fat diet (50% calories 
from fat) and after 8 weeks, insulin stimulated amino acid transport, insulin receptor (IR) 
tyrosine kinase activity and IR and IRS-1 tyrosine phosphorylation were normal in the muscles 
compared to rats fed control diet (Hansen et al., 1998). However, by 30 weeks on the high fat 
diet, a decrease in insulin stimulated tyrosine phosphorylation in muscle was observed (Hansen 
et al., 1998). GLUT4 at the cell surface was decreased by 26-36% in muscles compared to the 
control rats, at 8 weeks of consuming the high fat diet (Hansen et al., 1998). This indicates that at 
8 weeks of feeding high fat diets, muscle glucose transport is impaired (Hansen et al., 1998). 
This impairment is not because of changes in the composition of plasma membrane causing 
decreases in glucose transporters or function of the insulin receptor (Hansen et al., 1998). As 
well, reduced insulin receptor signaling is not the main cause of muscle insulin resistance 
developed from feeding high fat diets (Hansen et al., 1998). The last implication of this study is 
that dysfunctions in GLUT4 translocation to the plasma membrane is a major cause for the 
reduction in stimulated glucose transport (Hansen et al., 1998).  
Therefore, the decreased expression of IRS-2 causes impairment of the insulin signaling 
cascade. This affects glucose homeostasis and the absorption of glucose throughout the body, 
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and the translocation of GLUT4 to the plasma membrane, leading to insulin resistance and type 2 
diabetes. There is little information regarding the effects of decreased IRS-2 expression of other 
glucose transporters in obesity and type 2 diabetes.  
2.5.4 Inflammation Impact on Glucose Transport. There are indications that type 2 
diabetes is related to both endothelial and vascular dysfunction, and inflammation (Carvalho et 
al., 2013). There is a constant state of inflammation involved with type 2 diabetes, and increases 
in pro-inflammatory cytokines, including interleukins (IL) such as IL-1b, IL-6, IL-8 and TNF-a 
(Chang et al., 2012; Lee, 2013). These cytokines correlate with immune responses and type 2 
diabetes and are modulators of the homeostasis of glucose (Chang et al., 2012). When patients 
consume glucose and other macronutrients in excess, oxidative stress and cytokines are initiated, 
which block normal insulin signaling (Chang et al., 2012).  
Some of these cytokines are interleukins. Interleukins are soluble regulators that play a 
role during inflammation, modulating the level of intensity of the immune response and changes 
in physiology that occur because of inflammation (Hardin, Kroeker, Chung, & Gall, 2000). IL-
1a, IL-6 and IL-8 are characterized pro-inflammatory cytokines and IL-10 is an anti-
inflammatory cytokine (Hardin et al., 2000). IL-4 is produced by Th2 cells and is a pleiotropic 
cytokine and it regulates growth, differentiation and release of cytokines (Chang et al., 2012). 
Interleukins also play a role in regulating transport in the intestine (Hardin et al., 2000). In rabbit 
ileum, IL-1a has been found to inhibit the absorption of Na and Cl and initiates the secretion of 
anions in chicken intestine (Hardin et al., 2000). In comparison, IL-10 increases Na and Cl 
absorption and decreases Cl secretion in the small intestine of rats (Hardin et al., 2000). IL-6 has 
shown no response for Cl secretion in HT29 cl 19A colon cells, however, it decreases electrolyte 
transport.   
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The interplay between cytokines and glucose transporter expression was investigated 
through the mediation of renal glucose transporters during induced inflammation, where 
C57BL/6J mice were injected with either LPS or pro-inflammatory cytokines (Schmidt, Hocherl, 
& Bucher, 2007). Expression of SGLT2 and SGLT3 mRNA was largely decreased 12 hours after 
the injection of TNF-a, IL-1b and IFN-g (Schmidt et al., 2007). SGLT1 mRNA was increased 
following injection of the same cytokines (Schmidt et al., 2007). IL-6 decreased SGLT2 mRNA 
(Schmidt et al., 2007). The study concluded that the expression of these glucose transporters is 
regulated during experimental inflammation by pro-inflammatory cytokines in the kidney 
(Schmidt et al., 2007) . 
Furthermore, 3-O-methyl glucose transport was investigated in rabbit short circuited 
jejunum (Hardin et al., 2000). IL-1a, IL-6, IL-8 and IL-10 effects were tested (Hardin et al., 
2000). As well, the expression of SGLT1 was investigated in jejunal brush border membrane 
vesicles exposed to pro inflammatory interleukins, using western blots (Hardin et al., 2000).  IL-
1a, IL-6 and IL-8 elevated glucose absorption (increase in mucosal to serosal flux) significantly 
when compared to the control (Hardin et al., 2000). However, IL-10 did not affect glucose 
transport (Hardin et al., 2000). The expression of SGLT1 in brush border membrane vesicles was 
not different between the control and treated groups (Hardin et al., 2000).  
Therefore, inflammation and the subsequent release of interleukins does elevate the 
absorption of glucose in the intestine (Hardin et al., 2000). In addition, this information described 
is evidence that cytokines released in inflammation can influence the gene expression of glucose 
transporters, mainly SGLT1, SGLT2 and SGLT3.  
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2.6 Conclusion  
 
When carbohydrates are chronically consumed in excess, blood glucose levels are too 
high, which has been shown to cause impairment in insulin signaling and leads to insulin 
resistance. Excesses of high sugar and high fat diets cause many impairments throughout the 
body and leads to the development of metabolic diseases including obesity, prediabetes, 
metabolic syndrome and type 2 diabetes. The regulation of glucose transport is also impaired, 
and transcription of transporter genes is abnormal. Possible reasons for this impairment could be 
damaged insulin signaling or inflammation in the intestine. This following study filled this gap in 
the literature by investigating the causes for the changes in glucose transport in obese subjects 
and the effects of dietary or drinking inclusion of sucrose. As well, the electrogenic glucose 
transport and kinetics were investigated in the small intestine of mice. Together, the results of 
these experiments provided insight to the development of metabolic diseases, including obesity 
and type 2 diabetes, and potentially providing a treatment for these diseases by determining 
glucose transporter expression and affinity.     
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3.0 EXPERIMENTAL  
3.1 Purpose 
 
This work investigated changes in sodium dependent glucose transporter function and 
transcription in the intestine caused by chronically high levels of sugar, in both in drinking water 
and solid feed. Currently, there is little information known about this in the literature. It also 
began to decipher whether the changes in sodium dependent glucose transporter function and 
expression is a result of an adaptation to a particular nutrient (high sucrose) or whether it is 
instead due to obesity and the resulting inflammation or changes in insulin signaling caused by 
the diet and weight gain. The work provided a better understanding of the changes that occurs in 
gut sodium dependent glucose absorption during the development of obesity on high sucrose 
diets, that leads to type 2 diabetes and affects a large portion of the population. In addition, the 
effects and differences of drinking water or a solid diet as a chronic oral route of administration 
of sucrose were be investigated.  
The mice used in this study are a model to help determine what happens physiologically 
and molecularly to the intestine of obese individuals, in the development of metabolic syndrome 
because of consuming high sucrose diets. The 20% sucrose included in the drinking water 
mimics humans drinking unhealthy amounts of soft drinks, long term, which leads to high levels 
of blood glucose. The 35% sucrose included in the solid diet represents humans eating high sugar 
solid foods chronically. We can then observe the molecular changes occurring in the intestine 
and determine why these changes occur. 
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3.1.1 Hypothesis 
 
i. High sucrose in the diet, included in drinking water or solid feed will change sodium 
dependent glucose absorption in the GI through transcription and translational 
regulation, and these changes will correlate with inflammatory mediators in the 
intestinal epithelium and not with changes in insulin signaling.  
 
3.1.2 Objectives 
i. To investigate segmental differences in normal mice on a standard chow diet via Ussing 
Chamber. 
ii. To determine the effect of the high sucrose drinking water on the electrogenic glucose 
transport via Ussing chamber. 
iii. To determine if the effect of the high sucrose solid diet has similar electrogenic glucose 
transport as the high sucrose diet via Ussing chamber. 
iv. To determine the segmental differences in control mice and the effects of both of the high 
sucrose diets via qRT-PCR: 
o glucose transporters (SGLT1-6, GLUT4) 
o genes regulated by insulin (IRS-1, IRS-2 and GLUT4) 
o select pro-, anti- and regulatory inflammatory mediators 
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3.2 Materials and methods  
 
3.2.1 Experimental Animals and Management. In the first study, C57Bl6 female mice, 
obtained from Charles River were split into two groups. The first was the normal or control mice 
group and the second was the 20% sucrose treated drinking water group. Each group contained 
twelve mice. The mice participated in a feeding trial, which began on October 31, 2014. The 
drinking water sucrose treated mice received only one kind of drinking water, which was treated 
with 20% (w/v) sucrose and the control mice group received no treatment to their drinking water. 
Both groups of mice were fed a standard mouse chow, ProlabÒ Rat/Mouse/Hamster 300 from 
LabDiet (St. Louis, MO). This diet is grain based, and comes from whole plant ingredients, listed 
in Table 3.3. The amounts of the ingredients used in this diet are unknown, but it is known that 
wheat and corn are used for the carbohydrate source and make up 45% of the diet. The drinking 
water sucrose treated mice were 13 weeks old when the trial began, and were on the trial for 7.5 
to 9 months. A separate group of eight C57Bl6 female mice were fed a chow diet formulated 
with 35% solid sucrose inclusion (product number D12450B), from Research Diets, Inc. (New 
Brunswick, NJ) with regular drinking water. This 35% sucrose diet contained ingredients as 
listed in Table 3.3. This trial began in February/March of 2017 and mice were sacrificed a year 
later. Comparison of % calories from macronutrients and nutritional analysis for both diets can 
be found in Tables 3.1 and 3.2.  
Furthermore, the amount of sucrose consumed by each group of mice varied by 
treatment. The exact food intake for the standard chow diet (ProlabÒ Rat/Mouse/Hamster 300) 
that the control and drinking water sucrose treated mice received was not measured as it was 
given ad lib. However, per the manufacturer, mice consume approximately 5g of this diet/day, 
which contains 1% sucrose. Therefore, the amount of sucrose consumed by these two groups of 
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mice was around 0.05g/day. The drinking water sucrose treated mice drank an average of 7-12ml 
of the 20% sucrose water daily, and received 1.4-2.4g of sucrose per day, in addition to the 
sucrose provided by the standard chow diet (1.45-2.45g of sucrose/day in total). The sucrose in 
the drinking water also increases the % calories consumed from carbohydrate. In comparison, the 
solid sucrose treated mice ate approximately 3g of the 35% sucrose diet daily, and therefore 
consumed about 1.05g of sucrose per day. 
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Table 3.1: Comparison of % calories from macronutrients (diet information provided by 
manufacturers).  
 
 ProlabÒ 
Rat/Mouse/Hamster 300 
(control and drinking water 
sucrose treated mice) 
 
D12450B (solid dietary 
sucrose treated mice) 
Protein (%) 26 20 
Carbohydrate (%) 60 70 
Fat (%) 14 10 
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Table 3.2: Nutritional analyses of experimental diets. Nutrients expressed as % per ration (diet 
information provided by manufacturers). ND represents no data available for nutrient. 
 
Nutrient ProlabÒ 
Rat/Mouse/Hamster 300 
(control and drinking water 
sucrose treated mice) (%) 
D12450B 
(solid dietary sucrose 
treated mice)  
(%) 
Protein 22.5 16.9 
Fat (ether extract) 5.4 4.3 
Linoleic acid 1.73 1.39 
Linolenic acid 0.16 0.19 
Arachidonic acid 0 0 
Omega-3 fatty acids 0.34 0.19 
Total saturated fatty acids 1.75 1.14 
Total monounsaturated fatty 
acids 
1.6 1.30 
Polyunsaturated fatty acids ND 1.59 
Fiber  4.0 4.7 
Carbohydrate ND 67.4 
Nitrogen free extract (by 
difference) 
52 ND 
Starch 30.4 ND 
Glucose 0.1 ND 
Fructose 0.2 ND 
Sucrose 1.0 35.0 
Lactose 0 ND 
Energy (kcal/g) 3.46 3.76 
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Table 3.3: List of ingredients and diet formulation in decreasing order of ingredient inclusion for 
ProlabÒ Rat/Mouse/Hamster 300 (control mice and drinking water sucrose treated mice) and 
D12450B (solid dietary sucrose treated mice), respectively (diet information provided by 
manufacturers). Bold and italicized fonts indicate common ingredients between the two diets.  
 
ProlabÒ Rat/Mouse/Hamster 300 (control and 
drinking water sucrose treated mice) 
D12450B (solid dietary sucrose  
treated mice) (g/kg) 
Ground wheat Sucrose 350 
Dehulled soybean meal Corn Starch 315 
Wheat middlings Casein, 30 Mesh 200 
Ground corn Cellulose, BW200 50 
Fish meal Maltodextrin 10 35 
Porcine animal fat preserved with BHA Soybean Oil 25 
Dehydrated alfalfa meal Lard 20 
Calcium carbonate Potassium Citrate, 1 H2O 16.5 
Brewers dried yeast Dicalcium Phosphate 13 
Soybean oil Vitamin Mix V10001 10 
Salt Mineral Mix S10026 10 
Dicalcium phosphate Calcium Carbonate 5.5 
Monocalcium phosphate L-Cystine 3 
DL-methionine Choline Bitartrate 2 
L-lysine FD&C Yellow Dye #5_______ 0.05___ 
Choline chloride Total 1055.05 
Vitamin A acetate   
Menadione dimethylpyrimidinol bisulfate   
Magnesium oxide   
Ferrous sulfate   
Pyroxidine hydrochloride   
Cholecalciferol   
Biotin   
dl-alfalfa tocopherol acetate   
Vitamin B12 supplement   
Riboflavin   
Thiamin mononitrate   
Zinc oxide   
Folic acid   
Calcium pantothenate   
Nicotinic acid   
Manganous oxide   
Ferrous carbonate   
Copper sulfate   
Zinc sulfate   
Calcium iodate   
Cobalt carbonate   
Sodium selenite   
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3.2.2 Tissue Collection. The control and drinking water sucrose treated animals were 
sacrificed and tissues were collected between mid-June and the end of July 2015. The jejunum, 
ileum, and colon tissues were collected from the mouse intestine. Mouse sacrifice was staggered 
so that the length of time the mice received the 20% sucrose treated drinking water was equal. 
The same protocol was performed for the solid dietary sucrose treated mice, and sacrifice was in 
February/March of 2018. For all groups of mice, tissue samples were taken for RNA and stored 
at -80℃ for subsequent RNA extraction, RT qPCR, and qPCR experiments.  
 
3.2.3 Data Collection 
 
3.2.3.1 Ussing Chamber. For electrogenic experiments, tissues of the intestinal sections 
(jejunum, ileum, colon) from both groups of mice were mounted on the inserts and bathed in 
5mL of Krebs buffer on the apical and basal sides of the Ussing Chamber. Two portions from 
each of the segments were taken for the control and drinking water sucrose treated mice, whereas 
only one portion was taken for the solid dietary sucrose treated mice. The Krebs buffer 
contained: 114mM NaCl, 5mM KCl, 2.15mM CaCl2·2H2O, 1.1mM MgCl2·6H2O, 0.3mM 
NaH2.PO4·H2O, 1.65mM Na2HPO4 and 25mM NaHCO3 at pH 7.4 (Barry, Smyth, & Wright, 
1965; Clarke, 2009). No glucose was added to the buffer. The buffer in the chambers was 
maintained at physiological pH (7.4) by gassing with 95% O2 and 5% CO2, and controlling this 
with a needle valve and a temperature of 37°C was maintained throughout experiments (Clarke, 
2009; Ussing & Zerahn, 1951). The current (short-circuit current) was measured across the tissue 
through KCl agar bridges and reference electrodes (Clarke, 2009). Agar bridges are made by 
dissolving 3g of agar into 100ml of 3M KCl (Barry et al., 1965). This current was recorded on 
the computer in µA. The electrodes are connected to wires, and the wires are connected to a 
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voltage/current clamp, and the voltage was maintained at 0.001V (Clarke, 2009; Ussing & 
Zerahn, 1951). Current is applied to maintain the voltage at 0.001V (Barry et al., 1965). 
Once the tissue was mounted, the tissue left for 30 minutes to reach a base line (Clarke, 
2009). After this, glucose was added on the apical side of the chamber in increasing 
concentrations, starting at 1mM and ending at 50mM. The same amounts of mannitol were added 
to the basal side so that osmotic effects did not occur (Barry et al., 1965; Clarke, 2009). To 
conclude each experiment, inhibitors of glucose transporters were added to the apical sides to 
confirm glucose transporter presence. These inhibitors were dapagliflozin (AdooQ® Bioscience, 
Irvine, CA) and phloridzin dihydrate (Sigma-Aldrich Co., St. Louis, MO).  
Short circuit current (Isc) was measured during the experiments via electrodes and wires 
connected from the Ussing Chamber to the computer and displayed on Lab Chart in µA. This is 
used to measure resistances of the tissues and the changes in short circuit current in response to 
the glucose gradient and inhibitors.  
3.2.3.2 RNA Extraction and cDNA Synthesis. RNA was extracted from jejunum, ileum 
and colon tissues for all groups of mice, by homogenization in TRIzol® Reagent (Thermo Fisher 
Scientific, Canada) and following a protocol specific to the reagent (Rio, Ares, Hannon, & 
Nilsen, 2010). The concentration of RNA in each sample was determined by using a 
spectrophotometer, ND-1000 Spectrophotometer, NanoDrop (Thermo Fisher Scientific, Canada) 
(França, Freitas, Henriques, & Cerca, 2012). RNA was subsequently diluted to 600ng/uL for use 
in Reverse Transcription Polymerase Chain Reaction (RT-PCR). RT-PCR is performed to obtain 
cDNA using qScript™ cDNA SuperMix (Quanta Biosciences, Maryland, USA). RT-PCR was 
performed as previously described, following manufacturer protocol (Hatzel et al., 2015). The 
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thermal profile is as follows; 5 minutes at 25°C, 30 minutes at 42°C, and 5 minutes at 85°C. 
cDNA and was stored at -80°C until use.  
3.2.3.3 Quantitative Polymerase Chain Reaction (qPCR). For qPCR, GoTaq® qPCR 
Master Mix with SYBR® Green1 (Premega, Madison, USA) is used. This reaction is done in a 
Bio-Rad CFX96 Touch machine (Thermo Fisher Scientific, Canada). The volume of each 
reaction is 12.5uL and each reaction undergoes 40 cycles of qPCR, with GoTaq® HotStart 
Polymerase (Thermo Fisher Scientific, Canada). The protocol for qPCR is previously described 
and follows manufacturer protocol (Kupfer, White, Jenkins, & Burian, 2010). The activation step 
occurs at 95°C for 2 minutes, followed by denaturation at 95°C for 15 seconds, annealing and 
extension at 58°C (primer specific) for 1 minute and dissociation at 60-95°C. Serial dilutions of 
cDNA generate a standard curve for each gene, from which an efficiency for each primer is 
calculated. The housekeeping gene EFα1 is used to normalize the genes of interest.  
Primers (forward and reverse) were developed from known sequences in Mus musculus 
and obtained from NCBI (Bethesda, MD) (Table 3.4). Three primer sets for each gene were from 
Integrated DNA Technologies (Coralville, IA). Reactions were run in triplicates and a non-
template control was run with it to assess contamination.  
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Table 3.4: Mus musculus primer sequences 
 
Gene Forward Reverse Accession # 
SGLT1 GTGTACGGATCAGGTCATT 
 
GGGCAGTAGCTTCAGATAG 
 
NM_019810.4 
 
SGLT2 GCAGACCTTCGTCATTCT TCATTGCTCCCAGGTATTT 
 
NM_133254.3 
SGLT3 AGTCTTCATGCTTGCTATCT 
 
AGCGATCAGGCGAATAAG AF251268.1 
SGLT4 CCCTTGTTCCCTTTCTGT GTCTCTATACCTGTGCTCTTC NM_145551.4 
SGLT5 CTCATCGGTGTGAGTGTAG 
 
GAAGATGCCCAGGATGAA NM_001033227.2 
SGLT6 GACACAGTGAAAGGCTACT TAGGCAGCGACAGAAATG NM_146198.2 
IRS-1 AGTTGAGTTGGGCAGAATA CTGGTGAGGTATCCACATAG L24563.1 
IRS-2 GGAGACAATGACCAGTATGT 
 
GTGATGAGGCTGGGTATG 
 
NM_001081212.1 
GLUT4 CACTGGTCCTAGCTGTATTC 
 
GTTGCATTGTAGCTCTGTTC 
 
AB008453.1 
IL-1a GAGTCGGCAAAGAAATCAAG 
 
CAGAGAGAGATGGTCAATGG NM_010554.4 
IL-1b TACATCAGCACCTCACAAG 
 
AAACAGTCCAGCCCATAC 
 
NM_008361.4 
IFN-g GACCTAGAGAAGACACATCAG 
 
AACAGCCATGAGGAAGAG 
 
NM_008337.4 
TNF-a TCTACTCCCAGGTTCTCTT GGTTGACTTTCTCCTGGTAT NM_013693.3 
IL-6 CCATCCAGTTGCCTTCTT 
 
GTCTGTTGGGAGTGGTATC 
 
NM_031168.2 
IL-8 ACAAACAGCGTCGTAGAA GGCATGCCAGAGCTATAA D17630.1 
TGF-b1 CAACAATTCCTGGCGTTAC CCTGTATTCCGTCTCCTTG NM_011577.2 
IL-10 CAGCCGGGAAGACAATAA GGAGTCGGTTAGCAGTATG 
 
NM_010548.2 
IL-4 CGGCACAGAGCTATTGAT 
 
CCGATGATCTCTCTCAAGTG M25892.1 
IL-13 CAGCATGGTATGGAGTGT TATCCTCTGGGTCCTGTAG 
 
NM_008355.3 
EFα1 CTACAACCCTGACACAGTAG 
 
GTGACTTTCCATCCCTTGA 
 
X13661.1 
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3.2.4 Data and Statistical Analysis.  
3.2.4.1 Transport Kinetics and Ussing Chamber 
 
 Ussing Chamber data was analyzed using GraphPad Prism (GraphPad Software, La Jolla, 
CA). A Comparison of Fit test was done to determine whether Michaelis Menten kinetics or the 
Hill Equation was the best model to use to fit electrogenic glucose transport. For each diet and 
tissue, the Hill Equation was the preferred model to use (all p<0.001). In addition, for each 
mouse in each tissue and diet group, the electrogenic transport curve had a Hill Slope of >1, 
which indicates a sigmoidal fit to the curve. The Hill Slope refers to the degree of cooperativity 
(Lehninger, Nelson, & Cox., 2000). Therefore, the Hill Equation was used to fit to each graph of 
electrogenic glucose transport, where possible for all groups of mice. Vmax (transporter 
capacity) and K0.5 (value between the top and bottom of the sigmoidal curve or transporter 
affinity) values were then calculated from the sigmoidal curves of each individual mouse for 
each group. Km cannot be used to describe sigmoidal kinetics as proteins or enzymes that fit 
these kinetics do not follow the hyperbolic curve which is characteristic of Michaelis Menten 
kinetics (Lehninger et al., 2000).  
All data was then analyzed for statistical significance using SPSS software (SPSS Inc., 
Chicago, IL) and assessed for normality using a Kolmogorov-Smirnov test and a Levene’s test. 
A two-way repeated measure ANOVA used for electrogenic and inhibitor data sets to determine 
if the glucose transport for the solid dietary sucrose treated and drinking water sucrose treated 
mice were statistically significant from the control mice. A Tukey test was used for post hoc 
tests. A one-way ANOVA and post hoc Fishers LSD test were used for Vmax and K0.5 data for 
the solid dietary sucrose treated and drinking water sucrose treated mice compared to the control 
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mice, and for the jejunum and ileum of control mice an independent t-test was performed. 
Differences were considered significant if p<0.05.  
 
3.2.4.2 Percent Activity Remaining 
The % activity or % glucose-stimulated short circuit current remaining after inhibitor 
addition was calculated to identify the SGLT(s) involved in creating the electrogenic glucose 
current. The % activity of the transporters remaining after the addition of dapagliflozin was 
calculated by dividing the current at 300uM of dapagliflozin by the current at 50mM of glucose, 
and multiplying by 100%. As the inhibitors were added cumulatively, the % activity remaining 
after the addition of phloridzin dihydrate was calculated by dividing the current at 0.1mM of 
phloridzin dihydrate by the current at 300uM of dapagliflozin, and multiplying by 100%. 
Glucose-stimulated short circuit current at 50mM, without inhibitor (100% activity) was 
compared to the % of glucose-stimulated current remaining after the addition of both 
dapagliflozin (300uM) and phloridzin dihydrate (0.1mM) in a single sample t-test (test value = 
100), for normal mice jejunum and ileum (inhibitor effect), and for the control, solid dietary 
sucrose treated and drinking water sucrose treated mice in the jejunum and ileum (treatment 
effect).  
3.2.4.3 q-RT-PCR 
Validation of the primers’ dissociation curves from the reaction were analyzed. The 
standard curve with five 10-fold dilutions of cDNA resulting in amplification plots assessed the 
effectiveness of the primers. An efficiency was calculated using the equation 10(1/slope). A value 
between 1.75-2.5 was considered an efficient primer. The fold differences of each gene relative 
to normal mice in each tissue, normalized to the housekeeping gene (EFa1) were calculated. To 
assess whether gene expression of the solid dietary sucrose treated and drinking water sucrose 
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treated mice was different from the control mice, and whether gene expression of the three 
tissues in the normal mice were different from each other, a one-way ANOVA with a post-hoc 
Tukey test was carried out. Differences were considered significant if p<0.05. 
3.2.4.4 Average Weights 
For the average weights, a one-way ANOVA with a post-hoc Tukey test was performed 
to determine differences between the control mice and the solid dietary sucrose treated and 
drinking water sucrose treated mice. Differences were considered significant if p<0.05.  
 
3.3 Data Chapter: High Sucrose Diet Effects on Glucose Absorption  
 
3.3.1 Results  
 
Here we present the first report of segmental differences (jejunum, ileum and colon) in 
the short circuit current kinetics and expression of the sodium dependent glucose transporter 
genes in normal mice. The segmental differences in the normal mice were compared to mice 
treated with 20% sucrose in the drinking water or mice fed a 35% solid sucrose diet. The mice 
which received water treated with 20% sucrose developed obesity, whereas the mice which 
ingested a solid diet containing 35% sucrose did not. Vmax and K0.5 values were calculated for 
the induced currents stimulated by glucose, which displayed Hill Equation sigmoidal kinetics. 
Vmax refers to the capacity of the transporter, and the K0.5 refers to the affinity of the transporter  
 
3.3.1.1 Segmental Differences in Normal Mice 
 
Significant differences in glucose induced short-circuit were found between the different 
anatomical sections of the gastrointestinal tract. The Vmax, or maximal current values of the 
sodium dependent glucose transporter between the normal mice jejunum and normal mice ileum 
were not significantly different (Figure 3.1). However, the affinity for glucose absorption was 
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significantly different, with a much lower K0.5 or higher affinity in the ileum (p<0.001). Overall, 
a low affinity transporter was found in the jejunum, whereas a higher affinity transport was 
found in the ileum, with similar capacity between the two segments. Similar to what has been 
reported previously in mammalian literature, glucose absorption was not found in the colon 
(Kararli, 1995).  
Gene expression analysis was then performed on SGLT1 (SLC5A1), SGLT2 (SLC5A2), 
SGLT3 (SLC5A4), SGLT4 (SLC5A9), SGLT5 (SLC5A10) and SGLT6 (SLC5A11) to 
determine association between SGLT1 family members known to be associated with glucose 
absorption and observed kinetics. The gene expression of each individual gene in the jejunum, 
ileum and colon for the normal mice was normalized to both the housekeeping gene, EFa1 
(Table 3.5) and to the normal mice average (Figures 3.6, 3.9, 3.11). The relative expression of 
the high affinity low capacity SGLT1 was significantly higher in the jejunum compared to the 
ileum (p=0.005) and colon (p<0.001) (Table 3.5). Whereas the low affinity high capacity SGLT3 
had relative expression that was significantly higher in the jejunum than the ileum (p=0.007) and 
colon (p=0.002). As well, the very low affinity SGLT6 relative expression was significantly 
greater in the jejunum compared to the ileum (p<0.001), and colon (p<0.001) (Table 3.5). 
Interestingly, although there was lower gene expression of the SGLTs in the colon they were not 
significantly less than the ileum (Table 3.5).  
Inhibition of the sodium dependent glucose transporters, SGLT1 (SLC5A1) and SGLT2 
(SLC5A2) was performed to determine their contribution to the short-circuit current in the 
normal mice tissues. Interestingly, short-circuit current in this group of mice was partially 
inhibited by dapagliflozin, which is a SGLT2 (SLC5A2) inhibitor, but unaffected by phloridzin 
dihydrate, which is a SGLT1 (SLC5A1) inhibitor, added in succession after dapagliflozin. This 
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suggests the contribution SGLT2 transporters to the current, but also points to the contribution of 
other transporters not inhibited by dapagliflozin in the normal mice tissues. Overall, in the 
jejunum there was approximately 60% of transporter activity remaining after the addition of 
dapagliflozin, and about 100% activity remaining after the addition of phloridzin dihydrate. In 
comparison, in the ileum there was about 50% and 98% activity remaining after the addition of 
dapagliflozin and phloridzin dihydrate, respectively. The % activity remaining after addition of 
dapagliflozin in the jejunum and ileum was significantly different from 100% (both p=0.001) 
(Figure 3.2).  
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Figure 3.1: Vmax and K0.5 values for normal mice in the jejunum and ileum. Vmax and K0.5 
values were not detectable in the colon and thus is not shown in this figure. *p<0.05 in 
independent t-test, indicating significant difference between the tissues. Data is represented as 
mean ± SEM, n=13 mice (jejunum), 11 (ileum). 
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Figure 3.2: Percent glucose-stimulated short current remaining in the jejunum and ileum of 
normal mice after the addition of inhibitors dapagliflozin (300uM) and phloridzin dihydrate 
(0.1mM). *p<0.05 compared to glucose-stimulated short circuit current at 50mM, without 
inhibitor (100% activity) in single sample t-test (test value = 100). Data is represented as mean ± 
SEM. n=11 and 19 for dapagliflozin and phloridzin dihydrate, respectively in the jejunum. N=17 
and 18 for dapagliflozin and phloridzin dihydrate, respectively in the ileum. 
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Table 3.5: Segmental differences in relative gene expression of glucose transporters SGLT1-6 
normalized to the housekeeping gene EFα1 in the jejunum, ileum and colon of normal mice. 
Intestinal regions with different superscript letters indicated p<0.05 in Tukey posteriori test after 
1-way ANOVA. Data is represented as Mean ± SEM, N= 10 mice for each tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Tissue Average ± SEM 
SGLT1 Jejunum 0.2350 ± 0.0408a 
  Ileum 0.0917 ± 0.0293b 
  Colon 0.0155 ± 0.0017b 
    
 
SGLT2 Jejunum 1.2050-05 ± 9.5893-06 
  Ileum 1.4492-06 ± 5.933-07 
  Colon 0.0003 ± 0.0002 
    
 
SGLT3 Jejunum 0.0743 ± 0.0227a 
  Ileum 0.0108 ± 0.0061b 
  Colon 0.0005 ± 0.0002b 
    
 
SGLT4 Jejunum 0.0081 ± 0.0019 
  Ileum 0.0037 ± 0.0006 
  Colon 0.0043 ± 0.0020 
    
 
SGLT5 Jejunum 3.1134-06 ± 1.3907 -06 
  Ileum 1.1799-06 ± 2.308 -07 
  Colon 0.0001 ± 7.332 -05 
    
 
SGLT6 Jejunum 0.0106 ± 0.0017a 
  Ileum 0.0027 ± 0.0009b 
  Colon 0.0007 ± 0.0003b 
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3.3.1.2 High Sucrose Mice 
 
3.3.1.2.1 Average Weights  
The control mice had an average weight of 37.18 ± 1.42g, and the drinking water sucrose 
treated mice had a significantly higher average weight of 49.87 ± 1.26g (p<0.001) (Figure 3.3). 
In comparison, the solid dietary sucrose treated mice had a significantly lower average weight of 
30.04 ± 1.89g compared to the control mice (p=0.008). 
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Figure 3.3: Average body weights of mice taken at the end of each feeding trial after treatment 
with control, solid dietary sucrose treated mice and drinking water sucrose treated mice. *p<0.05 
compared to control mice in Tukey posteriori test after 1-way ANOVA. Data is represented as 
Mean ± SEM, n= 12 (control), 8 (solid dietary sucrose), 12 (drinking water). 
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3.3.1.2.2 Jejunum from mice treated with 20% sucrose in the drinking water  
At the end of the experiment, glucose absorption was significantly decreased in the 
jejunum of the mice treated with 20% sucrose in their drinking water compared to the control 
mice (p<0.001) (Figure 3.4). Specifically, in the jejunum, the electrogenic glucose transport was 
so poor in the drinking water sucrose treated mice that we were unable to fit the current to Hill 
Equation kinetics (Table 3.6). Given the decrease in current, it is not surprising that the jejunum 
of the drinking water sucrose mice had significantly less inhibition by dapagliflozin, an inhibitor 
of the low affinity high capacity transporter, SGLT2 (p<0.001) (Figure 3.5).  
Interestingly, the jejunum of the drinking water sucrose mice had a significant increase in 
SGLT1 expression but a significant decrease in SGLT3 expression compared to the control mice 
(p=0.001 and p=0.002, respectively) (Figure 3.6). Dominant SGLT1 expression, a high affinity, 
low capacity transporter could decrease current, or Vmax in this tissue. However, inhibition by 
phloridzin dihydrate was unchanged from control mice. The % activity remaining for the 
transporter present in this tissue was approximately 93% after the addition of both dapagliflozin 
and phloridzin dihydrate, and was also not significantly different from 100% (Table 3.7).  
The control or drinking water sucrose treated mice did not have impaired insulin 
signaling in the jejunum. This was indicated by unchanged levels of IRS-1 and GLUT4 and 
higher gene expression levels of IRS-2 in drinking water sucrose treated mice compared to the 
control mice (p=0.006). Thus, suggesting increased insulin signaling in jejunum of these 
animals. Only mild inflammatory changes were found, with the jejunum of the drinking water 
sucrose treated mice having a significant increase in the regulatory cytokine TGF-b1, compared 
to the control mice (p=0.001). The other segments did not show any change in inflammatory 
markers. 
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3.3.1.2.3 Jejunum from mice fed 35% solid dietary sucrose 
Similar to the jejunum of the mice treated with sucrose in the drinking water, overall 
electrogenic glucose transport for the solid dietary sucrose treated mice was significantly 
decreased from control mice (p<0.001) (Figure 3.4). However, unlike the jejunum, we could fit 
the electrogenic glucose transport in the mice fed 35% solid sucrose in the diet to the kinetic 
model used. Thus, demonstrating a lower Vmax and higher K0.5, resulting in lower affinity and 
lower capacity for the substrate (Table 3.6). However, these changes in Vmax and K0.5 for the 
solid dietary sucrose treated mice were not significantly different from the control mice. It 
should be noted that the solid dietary sucrose treated mice in each of the tissues, the jejunum, 
ileum and colon have low sample size of 8, that was reduced to 5 for Vmax and K0.5 calculations 
as some of the mice tissues had significant decreases in tissue resistances during the experiment, 
indicating tissue failure, and were not used in the study. The jejunum of the solid dietary sucrose 
treated mice had significantly less inhibition of dapagliflozin (p<0.001) and unchanged inhibition 
of phloridzin dihydrate compared to the control mice (Figure 3.5). After addition of dapagliflozin 
and phloridzin dihydrate, there was about 100% and 92% of transporter activity remaining, 
respectively, in the jejunum, but these differences were not significant from 100% of activity 
remaining (Table 3.7). Thus, it was unexpected to find a significant increase in SGLT2 
expression in the jejunum of the solid dietary sucrose treated mice compared to the control mice 
(p=0.042) (Figure 3.6).  The jejunum for this group of mice has a K0.5 suggesting a high capacity, 
low affinity transporter present, such as SGLT2. However, there was decreased current density, 
or Vmax in this tissue, and the current was not inhibited by dapagliflozin, which suggests that 
SGLT2 was not responsible for the small amount of current seen (Figure 3.4). The solid dietary 
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sucrose treated mice did not become insulin resistant in the jejunum and there was no change in 
inflammatory mediators compared to the control mice. 
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Figure 3.4: Changes in short circuit current (Isc) in response to increasing glucose 
concentrations (mM) in the jejunum, for control, solid dietary sucrose treated mice and drinking 
water sucrose treated mice. *p<0.05 compared to control mice at all glucose concentrations in 
Tukey posteriori test after 2-way Repeated Measure ANOVA. Data is represented as Mean ± 
SEM, n= 13 (control), 5 (solid dietary sucrose), 4 (drinking water sucrose).  
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Table 3.6: Vmax and K0.5 values for control, solid dietary sucrose treated mice and drinking 
water sucrose treated mice in the jejunum. No statistically significant differences were found 
among treatments. ND represents not detectable. Data is represented as mean ± SEM, n=13 
(control), 5 (solid dietary sucrose).  
 
 
 
 
 
 
 
 
 
 
 
  
 Jejunum 
Diet Vmax 
(uA/cm2) 
 
K0.5 (mM) 
Control 100.8 ± 24.2 
 
17.6 ± 0.9 
 
Solid Dietary 
Sucrose 
33.1 ± 10.1 
 
18.8 ± 2.8 
 
Drinking 
Water Sucrose  
ND 
 
 
ND 
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Figure 3.5: Changes in short circuit current (Isc) in response to increasing concentrations of 
dapagliflozin (uM) and phloridzin dihydrate (mM) compared to current detected in the absence 
of any inhibitor in the jejunum, for control, solid dietary sucrose treated mice and drinking water 
sucrose treated mice. *p<0.05 compared to control mice at all inhibitor concentrations in Tukey 
posteriori test after 2-way Repeated Measure ANOVA. Data is represented as Mean ± SEM, n= 
14 (control), 7 (solid dietary sucrose), 16 (drinking water sucrose).  
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Table 3.7: Percent glucose-stimulated short current remaining in the jejunum for control, solid 
dietary sucrose treated mice and drinking water sucrose treated mice after the addition of 
inhibitors dapagliflozin (300uM) and phloridzin dihydrate (0.1mM). *p<0.05 compared to 
glucose-stimulated short circuit current at 50mM, without inhibitors (100% activity) in single 
sample t-test (test value = 100). Data is represented as mean ± SEM. N=11 and 19 for 
dapagliflozin and phloridzin dihydrate, respectively for the control mice. N=7 for both 
dapagliflozin and phloridzin dihydrate for the solid dietary sucrose treated mice. N=20 and 21 
for dapagliflozin and phloridzin dihydrate, respectively for the drinking water sucrose treated 
mice. 
 
 
 
 
 
 
 
 
  
 Control (%) Solid Dietary 
Sucrose (%) 
Drinking 
Water Sucrose 
(%) 
Dapagliflozin 
 
60.14 ± 8.16* 100.37 ± 4.68 93.90 ± 11.94 
Phloridzin 
dihydrate 
 
101.81 ± 9.73 92.30 ± 4.50 92.39 ± 9.50 
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Figure 3.6: Jejunum gene expression changes determined by qRT-PCR after chronic feeding 
relative to control mice (left most column) average of mRNA expression of glucose transporters 
SGLT1-6, IRS-1, IRS-2, GLUT4 and pro-, anti- and regulatory inflammatory mediators 
normalized to the housekeeping gene EFα1 in the jejunum of solid dietary sucrose treated mice 
(middle column) and drinking water sucrose treated mice (right most column). *p<0.05 
compared to control mice in Tukey posteriori test after 1-way ANOVA. Data is represented as 
Mean ± SEM, n= 6-8 (control), 4-8 (solid dietary sucrose), 6-8 (drinking water sucrose).  
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3.3.1.2.4 Ileum from mice treated with 20% sucrose in the drinking water  
 
It appears that the electrogenic glucose transport for this group of mice was shut down in 
the jejunum and was shifted to the ileum, where there was a large increase in glucose transport. 
The drinking water sucrose treated mice had the highest electrogenic glucose transport in the 
ileum compared to the control mice, and this increase was significant (p<0.001) (Figure 3.7). 
This shift of transport to the ileum was associated with increasing capacity as indicated by an 
increase in Vmax and decreasing affinity, as indicated by an increase in K0.5 (p=0.031 and 
p=0.008, respectively) (Table 3.8). Interestingly, the ileum of the drinking water sucrose treated 
mice had unchanged inhibition of dapagliflozin and phloridzin dihydrate compared to the control 
mice (Figure 3.8). Thus, suggesting the change in current was not due to changes in SGLT1 or 
SGLT2. Additionally, there was approximately 69% and 99% of transporter activity remaining 
after the addition of dapagliflozin and phloridzin dihydrate, respectively. The 69% of activity 
remaining after the addition of dapagliflozin was significantly different from 100% (p=0.017), 
but the % activity after phloridzin dihydrate was not significant from 100% (Table 3.9). 
Although the drinking water sucrose treated mice had a larger increase in glucose short circuit 
current compared to the control mice, both groups had a decrease in the % activity remaining 
after the addition of dapagliflozin, which was not statistically significant, indicating that the 
inhibition was essentially the same between these two groups of mice.  
Gene expression analysis of the SGLT family members show that the ileum of the 
drinking water sucrose treated mice had a significant increase in SGLT1 compared to the control 
mice (p=0.036) (Figure 3.9). This was unexpected as SGLT1 is a low capacity, high affinity 
transporter. Additionally, the increase in Vmax and K0.5 was not accounted for by high capacity 
transporters such as SGLT2, which were unchanged.  
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No differences were found in expression of insulin signaling genes, as indicated by 
unchanged gene expression levels of IRS-1, IRS-2 and GLUT4 in the ileum, indicating that the 
changes seen where not due to insulin resistance or signaling.  However, as in the jejunum of the 
20% sucrose drinking water animals, significant increases in TGF-b1 compared to the control 
mice were found (p=0.036).  
 
3.3.1.2.5 Ileum from mice fed 35% solid dietary sucrose  
In contrast to the 20% sucrose drinking water mice, the ileum electrogenic glucose 
transport for the 35% solid dietary sucrose mice was significantly lower than the control mice 
(p<0.001) (Figure 3.7). The Vmax dropped significantly and the K0.5 increased significantly 
compared to the control mice (p=0.031 and p=0.004, respectively) (Table 3.8). This indicates a 
switch towards a lower affinity and higher capacity transporter present. Not surprisingly, given 
the decrease in electrogenic glucose absorption, the ileum of the solid dietary sucrose treated 
mice had significantly less inhibition of dapagliflozin (p<0.001) and unchanged inhibition of 
phloridzin dihydrate compared to the control mice (Figure 3.8).  After the addition of 
dapagliflozin and phloridzin dihydrate, there was 109% and 104% transporter activity remaining, 
respectively in the ileum. These differences in % activity remaining were not significant from 
100% (Table 3.9).  
Interestingly, this was not associated with any significant increases or decreases in gene 
expression of SGLT’s compared to the control mice (Figure 3.9). The solid dietary sucrose 
treated mice, compared to the control mice, did not become insulin resistant, and had no 
increases in insulin signaling. However, the ileum of the solid dietary sucrose treated mice has 
significantly decreased expression of TNF-a in comparison to the control group (p=0.014). This 
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contrasts the drinking water sucrose treated mice that had a significant increase in TGF-b1. 
Although, both likely represent resolving inflammation.  
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Figure 3.7: Changes in short circuit current (Isc) in response to increasing glucose 
concentrations (mM) in the ileum, for control, solid dietary sucrose treated mice and drinking 
water sucrose treated mice. *p<0.05 compared to control mice at all glucose concentrations in 
Tukey posteriori test after 2-way Repeated Measure ANOVA. Data is represented as Mean ± 
SEM, N= 12 (control), 5 (solid dietary sucrose), 14 (drinking water sucrose).  
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Table 3.8: Vmax and K0.5 values for control, solid dietary sucrose treated mice and drinking 
water sucrose treated mice in the ileum. *p<0.05 compared to control mice in Fishers LSD 
posteriori test after 1-way ANOVA. ND represents not detectable. Data is represented as mean ± 
SD, N=11 (control), 5 (solid dietary sucrose), 14 (drinking water sucrose). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Ileum 
Diet Vmax 
(uA/cm2) 
 
K0.5 (mM) 
Control 111.4 ± 17.5 
 
7.4 ± 1.0 
 
Solid Dietary 
Sucrose 
36.8 ± 18.0* 
 
13.0 ± 1.5* 
 
 
Drinking 
Water Sucrose 
 
179.0 ± 33.2* 
 
10.6 ± 0.6* 
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Figure 3.8: Changes in short circuit current (Isc) in response to increasing concentrations of 
dapagliflozin (uM) and phloridzin dihydrate (mM) compared to current detected in the absence 
of any inhibitor in the ileum, for control, solid dietary sucrose treated mice and drinking water 
sucrose treated mice. *p<0.05 compared to control mice at all inhibitor concentrations in Tukey 
posteriori test after 2-way Repeated Measure ANOVA. Data is represented as Mean ± SEM, N= 
20 (control), 8 (solid dietary sucrose), 22 (drinking water sucrose). 
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Table 3.9: Percent glucose-stimulated short current remaining in the ileum for control, solid 
dietary sucrose treated mice and drinking water sucrose treated mice after the addition of 
inhibitors dapagliflozin (300uM) and phloridzin dihydrate (0.1mM). *p<0.05 compared to 
glucose-stimulated short circuit current at 50mM, without inhibitors (100% activity) in single 
sample t-test (test value = 100). Data is represented as mean ± SEM. N=17 and 18 for 
dapagliflozin and phloridzin dihydrate, respectively for the control mice. N=7 and 8 for 
dapagliflozin and phloridzin dihydrate, respectively for the solid dietary sucrose treated mice. 
N=16 and 18 for dapagliflozin and phloridzin dihydrate, respectively for the drinking water 
sucrose treated mice.  
 
 
 Control (%) Solid Dietary 
Sucrose (%) 
Drinking Water 
Sucrose (%) 
Dapagliflozin 
 
50.86 ± 11.91* 109.72 ± 14.42 69.26 ± 11.46* 
Phloridzin dihydrate 
 
98.18 ± 14.60 104.83 ± 5.63 99.76 ± 8.27 
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Figure 3.9: Ileum gene expression changes determined by qRT-PCR after chronic feeding 
relative to control mice (left most column) average of mRNA expression of glucose transporters 
SGLT1-6, IRS-1, IRS-2, GLUT4 and pro-, anti- and regulatory inflammatory mediators 
normalized to the housekeeping gene EFα1 in the jejunum of solid dietary sucrose treated mice 
(middle column) and drinking water sucrose treated mice (right most column). *p<0.05 
compared to control mice in Tukey posteriori test after 1-way ANOVA. Data is represented as 
Mean ± SEM, N= 6-10 (control), 5-8 (solid dietary sucrose), 6-10 (drinking water sucrose). 
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3.3.1.2.6 Colon from mice treated with 20% sucrose in the drinking water 
 
Glucose transport for the drinking water sucrose treated mice was unchanged in the 
colon. Similar to the control and drinking water sucrose treated mice, glucose short circuit 
current was absent and did not fit the Hill Equation kinetics (Figure 3.10, Table 3.10). Since the 
colon of the control and drinking water sucrose treated mice had no increase in glucose short-
circuit current observed, inhibitors were not tested, and % activity remaining was not calculated.  
Interestingly, although the drinking water sucrose treated mice had no change in 
electrogenic glucose absorption, the colon had significant increases in expression of SGLT1 
compared to the control mice (p=0.012) (Figure 3.11). These mice did not become insulin 
resistant in the colon, and had an unchanged inflammatory response, compared to the control 
mice.  
3.3.1.2.7 Colon from mice fed 35% solid dietary sucrose 
Unexpectedly, the electrogenic glucose transport for the solid dietary sucrose treated 
mice was significantly higher than the control mice (p<0.001) (Figure 3.10). There seemed to be 
an overall shift in glucose transport to the colon of these mice, with transport shut down in the 
jejunum and ileum. This shift in glucose transport to the colon, is confirmed by transport with a 
low Vmax and K0.5 in this tissue compared to other segments in the control mice, providing 
evidence for a higher affinity and lower capacity transporter (Table 3.10). The colon of the solid 
dietary sucrose treated mice had no inhibition at the highest concentrations of dapagliflozin 
(p<0.001) or phloridzin dihydrate (data is not shown). Overall, there was about 97% and 98% of 
transporter activity remaining after the addition of dapagliflozin and phloridzin dihydrate, 
respectively, and both were not significantly different from 100%.  
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Although there was no inhibition by dapagliflozin, the colon of the solid dietary sucrose 
treated mice, had elevated expression of SGLT2 compared to the control group (p=0.013) 
(Figure 3.11). This group of mice also had no change in insulin signaling gene expression 
inflammatory mediators. 
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Figure 3.10: Changes in short circuit current (Isc) in response to increasing glucose 
concentrations (mM) in the colon, for control, solid dietary sucrose treated mice and drinking 
water sucrose treated mice. *p<0.05 compared to control mice at all glucose concentrations in 
Tukey posteriori test after 2-way Repeated Measure ANOVA. Data is represented as Mean ± 
SEM, N= 14 (control), 5 (solid dietary sucrose), 20 (drinking water sucrose). 
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Table 3.10: Vmax and K0.5 values for control, solid dietary sucrose treated mice and drinking 
water sucrose treated mice in the colon. Statistical tests were not calculated among treatments. 
ND represents not detectable. Data is represented as mean ± SD, N=5 (solid dietary sucrose). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Colon 
Diet Vmax 
(uA/cm2) 
 
K0.5 (mM) 
Control ND ND 
Solid Dietary 
Sucrose 
35.9 ± 12.7 
 
10.7 ± 2.2 
 
 
Drinking 
Water Sucrose 
 
ND ND 
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Figure 3.11: Colon gene expression changes determined by qRT-PCR after chronic feeding 
relative to control mice (left most column) average of mRNA expression of glucose transporters 
SGLT1-6, IRS-1, IRS-2, GLUT4 and pro-, anti- and regulatory inflammatory mediators 
normalized to the housekeeping gene EFα1 in the jejunum of solid dietary sucrose treated mice 
(middle column) and drinking water sucrose treated mice (right most column). *p<0.05 
compared to control mice in Tukey posteriori test after 1-way ANOVA. Data is represented as 
Mean ± SEM, N= 6-8 (control), 6-8 (solid dietary sucrose), 5-8 (drinking water sucrose).  
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3.3.2 Discussion 
 
3.3.2.1 Segmental Differences in Normal Mice 
 
There have been many studies carried out in a variety of species investigating the kinetics 
and transporters of glucose characteristic to each section of the intestine (Balen et al., 2008; 
Brown, 2000; Buddington, 1992; Buddington & Diamond, 1990; Buddington & Diamond, 1992; 
Csaky & Fischer, 1981; Dyer et al., 2002.; Herrmann et al., 2012; Kararli, 1995; Klinger et al., 
2018; Moran et al., 2010; Puchal & Buddington, 1992; Wang et al., 1997; Wood & Trayhurn, 
2003; Wright et al., 2007; Yoshikawa et al., 2011), but this has only been done to a very limited 
extent in the mouse intestine (Diamond et al., 1984), see Tables 3.11 and 3.12. However, none 
have investigated the sodium dependent electrogenic glucose absorption associated with the 
SGLT gene family. Here we addressed this gap in the literature. The significant difference in K0.5 
between the normal mice jejunum and ileum demonstrate that there are differences in 
transporters and affinities present in different segments of the intestine. As well, the novel 
sigmoidal transport found in the tissues of all groups of mice has not been previously reported.  
Our results correlate with previous studies findings of two separate kinetic systems in the 
intestine driving sodium dependent transport of glucose in the intestine (Table 3.11). In the brush 
border membrane vesicles of cat intestine, system 1 (major) had a lower affinity and higher 
capacity for glucose and system 2 (minor) had a higher affinity and lower capacity for glucose. 
Similarly in bovine jejunum brush border membrane vesicles, the uptake of glucose occurred by 
a major sodium-dependent system (low affinity) or a minor sodium-dependent system (high 
affinity) (Kaunitz & Wright, 1984; Wolffram et al., 1989). As well, rabbit jejunal brush border 
membrane vesicles exhibited two transport systems, the first had a low affinity and high capacity 
for glucose, and the second had a high affinity and low capacity for glucose (Dorando & Crane, 
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1984). However, it would seem from our data, that the mouse differs slightly on this theme as a 
high affinity, high capacity transport and a low affinity, high capacity transport system was 
found.  
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Table 3.11: Species Comparison of Segmental Differences in Transport Systems in the Small 
Intestine (adapted from literature review (Dorando & Crane, 1984; Kaunitz & Wright, 1984; 
Wolffram et al., 1989) and results section 3.3.1.1 Segmental Differences in Normal Mice). 
 
Species System 1 System 2 
Cat/bovine/rabbit Low affinity, high 
capacity 
High affinity, low 
capacity 
Normal Mice Low affinity, high 
capacity 
High affinity, high 
capacity 
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  Additionally, our results do again partially correlate with previous finding of kinetic 
intestinal segregation of two kinetic models along the intestine, although slightly novel than 
those previously described in mammals (Table 3.12). For example, it has been reported that pig 
ileum has a higher capacity (Vmax) to transport glucose, compared to the pig jejunum (Klinger 
et al., 2018). As well, in brush border membrane vesicle experiments with pig intestines, the 
mean Vmax in the ileum was 2-fold greater than the mean Vmax in the jejunum (Herrmann et 
al., 2012). The Km was slightly higher in the jejunum of the pig intestine, compared to the ileum 
but this difference was not significant (Herrmann et al., 2012). Similar findings were found for 
the equine model (Dyer et al., 2002.)  However, this differed from the rat model (Wang et al., 
1997), which had a higher Vmax and a lower Km in the jejunum, compared to the ileum.  This 
study, presents another mammalian variation to the differences in the kinetic segregation, with a 
similar Vmax between the jejunum and ileum, but a K0.5 in the jejunum is about 2.4 times higher 
in the jejunum than in the ileum. Additionally, our results also correlate with previous findings 
demonstrating very little colonic glucose absorption in the normal mice (Kararli, 1995). 
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Table 3.12: Species Comparison of Segmental Differences in Vmax and Km/K0.5 in the Small 
Intestine (adapted from literature review (Dyer et al., 2002.; Herrmann et al., 2012; Klinger et al., 
2018; Wang et al., 1997) and results section 3.3.1.1 Segmental Differences in Normal Mice). ND 
represents no difference between segments. Up arrows indicate high Vmax/Km/K0.5 and down 
arrows indicate low Vmax/Km/K0.5 in each tissue. 
 
 
 Jejunum Ileum 
Species Vmax Km/K0.5 Vmax Km/K0.5  
 
Porcine/equine 
    
 
Rat 
    
 
Normal Mice 
 
ND 
  
ND 
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Functional kinetic and pharmacological inhibition analysis, along with gene expression 
analysis of the well-known SGLT1, a high affinity, low capacity transporter, and the well 
characterized SGLT2, a low affinity, high capacity transporter did not fully account for the 
kinetic segregation seen. Although, the jejunum had the highest expression of SGLT1, similar to 
previous findings (Balen et al., 2008; Herrmann et al., 2012; Yoshikawa et al., 2011), it had a 
higher K0.5 than the ileum, indicating a lower affinity, high capacity transporter present in the 
jejunum, like SGLT2 (Jurczak et al., 2011). However, SGLT2 expression was unchanged 
between intestinal segments (Table 3.5), although it is often found to be expressed mostly in the 
ileum (Wood & Trayhurn, 2003). Additionally, only ~ 50% inhibition was obtained with thes 
dapagliflozin and relatively no inhibition was obtained by phloridzin dihydrate, which are 
SGLT2 and SGLT1 inhibitors, respectively. Overall, these findings do not fit kinetics dominated 
by either SGLT1 or SGLT2 in the proximal intestine and do not suggest a contribution from 
these two genes to produce the observed currents.   
      Similarly, the lower K0.5 in the ileum represents a high affinity transporter present, such as 
SGLT1 (Ritze et al., 2014). However, SGLT2 expression was unchanged between segments and    
~ 50% of initial transporter activity remained after inhibition with dapagliflozin and ~100% 
remained after inhibition with phloridzin dihydrate. Additionally, the tissue did not fit the 
classical hyperbolic Michaelis Menten kinetics of the isolated SGLT1 and SGLT2 family 
members, suggesting a regulatory mechanism or the expression of novel or novel combinations 
of transporters. To this end, the significantly elevated expression of SGLT3 and SGLT6 in the 
jejunum compared to ileum, which are suspected to be a low affinity (Diez-Sampedro & 
Barcelona, 2011; Wright et al., 2007), could account for the segmental difference of a lower 
affinity and similar Vmax in the jejunum and ileum. Thus, the kinetics that results from the 
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higher expression of SGLT1 in the jejunum would be tempered by SGLT3 and SGLT6. This 
supports the sigmoidal kinetics described here, that could be explained by a combined expression 
of equally dominant, but drastically different SGLT kinetic orthologues.       
Another possible explanation for this divergence from the classical kinetics, is that 
SGLT1 and SGLT2 undergo some type of post-translational modification in mice, causing them 
to modify their transport properties. Glycosylation post-translational modification of SGLT1 has 
been shown (Kothinti, Blodgett, North, Roman, & Tabatabai, 2012). The site for this 
glycosylation in human SGLT1 is conserved with other SGLTs (Kothinti et al., 2012). Such 
glycosylation could also affect SGLT3 and homologous SGLT2, in addition to SGLT1 (Kothinti 
et al., 2012) and could partially account for differences in segmental kinetics observed if it varied 
between intestinal segments. Although the importance of phosphorylation of SGLT1 (SLC5A1) 
has not been fully determined (Klinger et al., 2018), it is a well-known occurrence and may 
account for some of the segmental differences seen (Herrmann et al., 2012). Such cell signaling 
phosphorylation events have been shown modify SGLT kinetics, as the co-expression of RS1, 
decreased the Vmax of SGLT1 in oocytes (Arndt et al., 2000). 
Finally, the possibility still exists that a separate orphan transporter yet to be identified 
contributes to the short circuit current observed in the intestine of the normal mice, deviating 
transport away from classical SGLT1 and SGLT2 kinetics.  
Overall, when fed a standard chow diet, the sodium or electrogenic glucose absorption 
kinetics in the mouse follow 2 systems, with intestinal segmental segregation of the kinetics 
similar to none of the studies found in the literature, with similar Vmax between ileum and 
jejunum, but a and higher K0.5 in the jejunum. However, this drastically changed when the 
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animal was fed high levels of sucrose in the drinking water or when formulated into the feed 
mimicking poor North American diets.  
 
3.3.2.2 Sucrose Effect in the Jejunum 
 The glucose induced short-circuit current in the drinking water sucrose treated mice 
jejunum was significantly decreased compared to the control mice, and did not fit Hill Equation 
kinetics, and there was no inhibition by dapagliflozin or phloridzin dihydrate. Thus, suggesting a 
decrease in the SGLT2 and SGLT1 transport found in the control mice. Paradoxically, the 
jejunum of these mice had increased expression of SGLT1 and there was no significant change 
in SGLT2 expression. Similar to the drinking water sucrose treated mice, the solid diet sucrose 
treated mice had significant increases in SGLT2, but there was decreased transport compared to 
the control mice and the remaining current was not inhibited by dapagliflozin or phloridzin 
dihydrate. Indicating that the loss of current was unlikely due to changes in gene expression and 
more likely the result of post-transcriptional modification discontinuing SGLT’s ability to 
transport glucose. 
This putative post-transcriptional modification or regulation is unlikely due to a decrease 
in insulin signaling, in the drinking water sucrose treated mice. This is a potential cause as the 
drinking water sucrose treated mouse is a model for obesity, insulin resistance and development 
of type 2 diabetes. But, we only observed an increase of IRS-2 in the jejunum of the drinking 
water sucrose treated mice, indicating increased insulin signaling and not an impairment in 
insulin. If a subject is insulin resistant, IRS-2 expression will be downregulated, as the insulin 
signaling pathway is impaired in these subjects (Hennige et al., 2003; Pessin & Saltiel, 2000; 
Saltiel & Kahn, 2001). As well, GLUT4 gene expression and translocation is impairment with 
changes in insulin signaling, and no such changes where observed in the gut of these mice 
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(Hansen et al., 1998; Scheepers et al., 2004). In addition, insulin has been shown to increase the 
Na/glucose transport through SGLT2 at 400pM, but does not affect Na/glucose transport through 
SGLT1 at this concentration (Ghezzi & Wright, 2012). However, there was not a consistent 
increase in SGLT2 expression for each of the diets or tissues.  
The increase in TGF-b1 in the jejunum could be a sign of a resolved inflammatory 
response in this group of mice treated with 20% sucrose drinking water chronically. TGF-b1 is 
one of three isoforms of TGF-b1, and is the most highly expressed of the three in the immune 
system (Worthington, Fenton, Czajkowska, Klementowicz, & Travis, 2012). This cytokine plays 
a pivotal role in regulating immunity and has multiple effects on numerous cells in the immune 
system (Worthington et al., 2012). TGF-b1 is described as having anti-inflammatory effects on 
the immune system, and therefore decreasing the inflammatory response (Worthington et al., 
2012). That being said, cytokines have been shown to have a significant impact on the 
expression of SGLT1, SGLT2 and SGLT3 (Schmidt et al., 2007). mRNA for these transporters 
where significantly changed 12 hours after the injection of TNF-a, IL-1b and IFN-g (Schmidt et 
al., 2007). Thus, the inflammatory effects due to the high sucrose diet could have driven some of 
the changes seen in the drinking water sucrose treated mice. However, aside from IRS-2 and 
TGF-b1, there are no significant changes in the expression of the other insulin signaling genes 
and inflammatory mediator genes, and these changes are not consistent across tissue sections. 
Additionally, the lack of impairment in insulin signaling and an inflammatory response in the 
jejunum of the solid dietary sucrose treated mice provides strong evidence that the changes in 
glucose transporter in the jejunum are not due to changes in insulin signaling or an inflammatory 
response.  
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3.3.2.3 Sucrose Effect in the Ileum 
The increased glucose induced short-circuit current in the ileum of the drinking water 
sucrose treated mice cannot be explained by any of the gene expression data, and the inhibitor 
data did not demonstrate an increase in the inhibition by dapagliflozin or phloridzin dihydrate 
compared to control mice. This increased current, demonstrated a significant increase in K0.5 and 
Vmax. Thus, indicating a shift to a lower affinity, higher capacity transporter. So, given the lack 
of inhibited current and kinetic changes, the significant increase in SGLT1 gene expression could 
not account for this difference. Either the posttranslational modification of the assessed 
transporters (SGLT 1 – 6) or an orphan transporter would have to be responsible for this change 
seen in the ileum subjected to 20% sucrose drinking water. In contrast, the ileum of the solid 
dietary sucrose treated mice had a decreased current. Again, none of the gene expression could 
explain this drop in current. There was also a significant decrease in inhibition by dapagliflozin 
on the remaining current, with greater than 100% of activity remaining after the addition of both 
inhibitors.    
As changes were not seen in the expression of insulin signaling genes and only minor 
changes in inflammation were found, the cause for these changes in glucose transporter gene 
expression do not seem to be linked to inflammation or dysfunctions in the insulin signaling 
pathway. Interestingly, again in the drinking water sucrose treated mice, as in the jejunum, the 
ileum also had a significant increase TGF-b1, which the solid dietary sucrose treated mice did 
not, in either tissue. However, the solid dietary sucrose treated mice did have a significant 
decrease in TNF-a, which is unique to this diet and tissue, but does indicate a resolving 
inflammatory response, due to the downregulation. Thus, resolving inflammation does seem to 
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be consistent between treatments in this segment. However, is not consistent between all 
segments and treatments. 
 
3.3.2.4 Sucrose Effect in the Colon 
The control and drinking water sucrose treated mice displayed normal absence of glucose 
transport in the colon that did not fit Hill Equation kinetics. Interestingly, it did have a significant 
increase in SGLT1 compared to controll mice, suggesting tissue specific post translational 
modification and regulation preventing its function in this segment.   
 In comparison, the solid dietary sucrose treated mice had a significantly increased 
glucose dependent current. This was associated with fold change of just below 2 for SGLT2 in 
the colon of solid dietary sucrose treated mice, giving a possible explanation for the observed 
current.  However, SGLT2 expression was increased by approximately 4.5-fold in the jejunum of 
these solid dietary sucrose treated mice, with an observed decrease in current compared to the 
control mice. Additionally, the lack of inhibition by dapagliflozin (97% activity remaining), 
indicated that SGLT2 was likely not responsible for the current. Again, suggesting post-
translational modification of the SGLTs assessed or an orphan transporter.  
Finally, this cause for the observed increase in SGLT1 gene expression in the colon of the 
drinking water sucrose treated mice and the increase in SGLT2 and orphan current in the solid 
dietary sucrose treated mice unknown. However, it is likely not caused by inflammation or 
dysfunctions in the insulin signaling pathway, as the colon of the drinking water sucrose treated 
mice and solid dietary sucrose treated mice did not show changes in the expression of insulin 
signaling or inflammatory genes.  
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3.3.2.5 Novel Sigmoidal Transport Kinetics 
Interestingly, the preferred model to fit the glucose short-circuit current observed in the 
tissues of the normal or control, solid dietary sucrose treated mice and drinking water sucrose 
treated mice was the Hill Equation, instead of the Michaelis Menten kinetics. Suggesting that 
either multiple transporters working in concert, or some type of allosteric regulation of the SGLT 
transporters is present in the mouse gut. Specifically, the fit to the Hill Equation represents 
sigmoidal transport kinetics for the transporters responsible for the glucose short-circuit current 
in these groups of mice. Sigmoidal or cooperative binding represents a transition from a low 
affinity to a high affinity state (Lehninger et al., 2000). Sigmoidal transport kinetics could mean 
that there is one transporter responsible for the current produced that is acting allosterically. 
When a ligand binds to one site of an allosteric protein, the binding properties of another site on 
the same protein are affected (Lehninger et al., 2000). This ligand binding therefore induces 
conformational changes that make the protein more active or less active (Lehninger et al., 2000).  
However, the transporters studied belong to the SGLT family, for which sigmoidal 
transport kinetics have not yet been identified. Suggesting an orphan SGLT like transporter with 
allosteric properties. Alternatively, there are no allosteric properties and there are two 
transporters working together to create the current observed. This is highly possible as SGLT1 
and SGLT2 are known to have very different affinity kinetics and if expressed in the same tissue, 
they could produce a sigmoidal type response. However, such a response in Ussing chambers has 
not previously been reported in other species. This suggests that mouse intestinal tissue is either 
be more heterogeneous in its SGLT expression and function, such that it has sigmoidal kinetics 
or that mice possess an allosterically regulated SGLT and/or orphan transporter.      
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3.3.2.6 Potential Orphan Transporters 
The sucrose in both diets cause a shift in glucose induced short circuit current caudally 
down the intestine with the proximal tissues decreasing capacity and caudal tissues increasing 
capacity. Interestingly, the increased glucose short circuit current observed in the caudal tissues 
did not associate with any change in expression of SGLT genes assessed.  Additionally, the 
increase in the glucose induced short circuit was not inhibited by either dapagliflozin or 
phloridzin dihydrate, ruling out SGLT1 and SGLT2.  Thus, a change in expression of SGLT 1- 6 
is unlikely to account for this increase in Vmax and K0.5. Suggesting some type of major post 
translational regulation of SGLT 1 – 6, or the expression of orphan transporters.   
One possibility for the gene identity of a putative orphan transporter, are the other 6 
SGLT or SLC5A gene family members. However, the majority these members have not been 
reported to transport glucose, with the exception is SMIT1 (Wright, 2013). However, SMIT1’s 
primary function is the transport of myoinositol and its expression in the gastrointestinal tract is 
minimal compared to other SGLT’s and proper assessment of SMIT1 is beyond the scope of this 
study. Similarly, other potential candidates are the sodium-coupled monocarboxylate transporter 
(SMCTs) family SLC5A8 and SLC5A12. However, their ability to transport glucose has not 
been reported. That being said, substrate promiscuity could be possible. The SLC5A8 gene 
product is a high affinity, low capacity transporter for monocarboxylates and is expressed in the 
apical membrane of epithelial cells in the intestine and proximal tubule (Ganapathy et al., 2008). 
This transporter absorbs short chain fatty acids in both the colon and small intestine, and 
reabsorbs lactate and pyruvate in the kidney (Ganapathy et al., 2008). Additionally, there is 
SLC5A12, which is a low affinity, high capacity transporter (Ganapathy et al., 2008). It is also 
found to be expressed in the apical membrane of epithelial cells in the intestinal tract and in the 
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proximal tubule of the kidney (Ganapathy et al., 2008). It has a tumor-suppressive function that 
allows it to moderate the uptake of butyrate, proprionate and pyruvate (Ganapathy et al., 2008).  
There are also many amino acid transporters that are Na dependent and could also be the 
orphan transporters responsible for the glucose short circuit current observed in this study. For 
example, the amino acid transporter B0AT1 (SLC6A19), is a Na dependent transporter that 
transports neutral amino acids. (Broer, 2008; Gilbert, Wong, & Webb, 2008). This transporter 
has a high affinity for neutral amino acids and a low affinity for basic and acidic amino acids 
(Drew, Estrada, Van-Kessel, & Maenz, 2002). It also has low substrate specificity (Drew et al., 
2002). A study investigating the expression of amino acid transporters along the gastrointestinal 
tract in Turbot found cationic and neutral transporters, including B0AT1 to be rich in the whole 
intestine (Xu et al., 2016). 
 
3.3.2.7 Adaption to Diet 
Weighing the evidence, obesity and related changes of insulin signaling and 
inflammation did not appear to be the cause of the changes seen in the glucose induced short 
circuit current in this study. Although the mice treated with 20% sucrose drinking water became 
obese and the 35% sucrose solid feed treated mice weighed less on average compared to the 
control mice, both groups had a caudal migration of the glucose induced short circuit current. 
This is not too surprising as the sucrose and the resulting “nutrient”, glucose, fed at high 
concentrations, likely have physiological effects other than weight gain. For example, it is said 
that glucose in the lumen regulates its own transport by activating sweet taste receptors and by 
increasing the availability of glucose transporters, such as SGLT1 (Baud et al., 2016). In 
addition, consuming a diet high in carbohydrates, causes metabolic abnormalities such as 
increased blood pressure and levels of methylglyoxal (Dhar et al., 2013), but these abnormalities 
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are not always presented with increased body weight (La Fleur et al., 2011). In comparison, 
ingestion of beverages sweetened with sugar often causes increases in weight gain, but with 
similar blood pressure changes, along with changes in insulin signaling and the development of 
type 2 diabetes (Malik et al., 2010; Schulze et al., 2004). Interestingly, decreases in insulin 
signaling changes are often associated with obesity, but this was not found in the intestine of 
these obese mice. However, the jejunum of the drinking water sucrose treated mice did have an 
increase in IRS-2, demonstrating increased insulin signaling. Although, this could be an obesity 
effect, it was not consistent between segments and models and is thus unlikely to be the cause of 
change in current. Alternatively, the inflammation from the high sucrose could drive some of the 
transport changes seen. High glucose consumption is associated with systemic inflammation due 
to methylglyoxal production, and the resulting cytokines could modulate glucose homeostasis 
and transporter expression and function (Chang et al., 2012; Hardin et al., 2000; Schmidt et al., 
2007). Although, TGF-b1 was found to be significantly increased in the jejunum and ileum, this 
functional change was not consistent between segments. Additionally, such a response was not 
seen in the jejunum of the solid dietary sucrose treated mice, with only a mild TNF-a in the solid 
dietary sucrose treated mice ileum. Thus, given the inconsistency and poor association between 
insulin signaling changes, inflammatory response and current changes, it appears that the change 
is most likely directly driven by glucose. This is consistent with previous studies in the literature 
which conclude that different sources of carbohydrate in the diet can affect the gene expression 
of glucose transporters, especially SGLT1 jejunum (Cao et al., 2018; Dyer et al., 2009; Klinger, 
Noci, et al., 2013; Klinger, Zurich, et al., 2013; Moran et al., 2010; Saddoris et al., 2007). 
Although, function was often not assessed in these studies. Our functional finds are also 
consistent from studies mice, using intestinal sleeves in vitro, to determine the effects of 
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carbohydrates in the diet on monosaccharide transport (Diamond et al., 1984). The normal group 
received no sucrose in the diet and had similar glucose transport along each section of the small 
intestine (Diamond et al., 1984), unlike our findings. However, the mice on the carbohydrate diet 
did have an increased glucose transport in the ileum (Diamond et al., 1984), similar to our 
findings.  
Overall, the cause for the observed changes in electrogenic glucose current and glucose 
transporter gene expression do not seem to be attributed to an inflammatory response or 
dysfunctions in the insulin signaling pathway. Therefore, these changes could be due to the 
various amounts of sucrose consumed by the different treatment groups of mice, as a result of the 
route of administration of the sucrose. The drinking water sucrose treated mice consumed an 
extra 1.4-2.4g of sucrose per day. The route of delivery for the extra sucrose provided to this 
group of mice was delivered in the drinking water, therefore causing the mice to consume large 
amounts of an osmotically active sugar hypertonic solution, without access to normal drinking 
water to balance any osmotic imbalances. Thus, the drinking water sucrose treated mice would 
have continually drank the sugar water to attempt to feel hydrated, becoming obese in the 
process as they consumed the extra calories chronically present in their drinking water. In 
comparison, the route of administration of sucrose for the solid dietary sucrose treated mice did 
not pose same problem in achieving osmotic balance. Therefore, this group of mice ate and 
drank normally, and received less sucrose per day than the drinking water sucrose treated mice, 
and did not become obese. It can then be speculated that the route of administration, the drinking 
water or a solid diet, can affect the amount of sucrose consumed in different treatment groups, 
and may play a role in the development of obesity and changes in glucose short circuit current 
and glucose transporter gene expression. 
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4.0 CONCLUSION 
 
This study provides a better understanding of the sodium dependent glucose absorption 
along the gastrointestinal tract of mice and the effects of high sugar diets, in drinking water and 
solid feed on that process.  Overall, mouse electrogenic sodium dependent glucose absorption 
demonstrated intestinal segmental kinetic differences not previously described in other 
mammals. Specifically, a lower affinity transporter was found in the jejunum and a higher 
affinity transporter was found in the ileum, but a similar capacity in both segments. This 
difference is likely partially due to mild SGLT gene expression segregation between segments. 
Specially, higher expression of SGLT3 and SGLT6 in the jejunum. Additionally, in all segments, 
the glucose short-circuit current fit sigmoidal transport kinetics, which has not been previously 
reported in other animals. Either this is a result of yet uncharacterized mouse SGLT kinetics or a 
more heterogenic expression of SGLT genes with different transport kinetics between tissues.  
Interestingly, this baseline transport on a balanced chow diet was highly modified when the 
animals were chronically give 20% sucrose in the drinking water, or 35% sucrose in the feed. 
This has importance in North American, where the diets are high in sucrose, which is thought to 
contribute to the development of metabolic syndrome and type 2 diabetes, which are diseases 
affecting a large portion of the population. Both high sucrose in the drinking water and the solid 
feed cause shifts in the transport kinetics from cranial to caudal in the tissues, increasing the 
capacity (Vmax) and lowering the affinity (K0.5), both caudally. Additionally, this increase in 
transport seems to be mediated through a yet to be identified transporter. As gene expression and 
specific SGLT inhibitor analysis could not account for the change. Thus, suggesting the change 
was due to the expression of an orphan transporter. Although inflammatory changes were 
observed, the changes were not consistent between intestinal tissues segments and models. 
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Similarly, there does not seem to be an association in the changes in current of the diets and 
insulin signaling. Again, the changes in insulin signaling gene expression were not consistent 
between intestinal segment and models. Additionally, obesity does not seem to be a factor in the 
changes in glucose absorption, as both treatments with high in sucrose produce similar changes 
in glucose induced current, but only the drinking water sucrose treated animals were obese. 
Altogether, the results indicate that mouse electrogenic glucose absorption differs from other 
species previously characterized. In addition, the route of administration, both the high sucrose in 
the diet and in the drinking water was found to be very important, as both routes can vary the 
amount of sucrose the animal consumes. Consequently, the route of sucrose in the drinking water 
can lead to obesity, whereas the route of sucrose in solid feed does not. Overall, both routes have 
effects on the small intestine, altering glucose transport and absorption.  
 
5.0 STUDY LIMITATIONS  
 
 One of the limitations of this research is the lack of consistency between the standard 
chow and solid diet with 35% sucrose included and the two separate trials. It would have been 
ideal to have one trial in which both treatment groups could be compared more accurately to the 
control or normal mice group. In addition, all three groups of mice would be exposed to the same 
environmental parameters, avoiding confounding factors that could have be different between the 
two trials. As well, having diets with similar inclusion rates for all ingredients except for sucrose 
would have made it more clear which nutrient the high sucrose mice adapted to. Increasing the 
sample size for each of the groups of mice would also have been more representative of the 
whole mice population, and the effects that occur from consuming high sucrose diets, in the 
drinking water or solid feed.  
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The results of this study would be enhanced if the protein content for each of the glucose 
transporters, mediators of insulin signaling and inflammatory mediators was assessed, as mRNA 
gene expression data does not provide insight to whether the genes are translated into functional 
proteins. The phosphorylation of IRS-1 and IRS-2 would also be helpful to investigate. Knowing 
if these proteins undergo phosphorylation or not provides more evidence for impaired insulin 
signaling or dysfunctional insulin signaling. Investigating the hormones that are involved in 
satiation, such as leptin, would also enhance the study results. The expression or protein content 
of these hormones could help explain reasons why subjects continually drink sugar sweetened 
beverages and develop obesity, in addition to the hypertonicity of these beverages.  
Future direction of this study would be to investigate whether there is decreased insulin 
signaling in the peripheral tissues (liver and muscle) of these mice. As well, determining the 
orphan transporters described in this study through Ussing Chamber experiments, qPCR or 
Western Blots would be another future direction. This would include gene expression analysis of 
the other SGLT/SLC5A family members.  This data chapter has not been submitted for 
publication. 
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